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Chapter 1
General Introduction
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General Introduction
1.1 Cervical cancer
In 2005, there were, according to WHO projections, over 500,000 new cases o f cervical 
cancer, o f which over 90% were in developing countries where cervical cancer is the leading 
malignancy among women. It is estimated that over 1 million women worldwide currently have 
cervical cancer, most o f who have not been diagnosed, or have no access to treatment that could 
cure them or prolong their life. 1
In the same year, almost 260,000 women died of the disease, nearly 95% o f them in 
developing countries, making cervical cancer one ofthe gravest threats to women's lives. Without 
urgent action, deaths due to cervical cancer are projected to rise by almost 25% over the next 10 
years. Prevention o f these deaths by adequate screening and treatment will contribute to the 
achievement o f the Millennium Development Goal (MDG), since the biggest impacts of cervical 
cancer are on poverty, education and gender equity, the first three Millenium Development 
Goals.2 While reproductive health in general and cervical cancer prevention in particular, are not 
explicitly mentioned among the MDGs, they are implied, and it is certain that women cannot 
contribute to sustainable development without good health.
In many developing countries, access to health services is limited and screening for 
cervical cancer either is non-existent or reaches few o f the women who need it. In these areas, 
cervical cancer is the most common cancer in women and the leading cause o f cancer death 
among women. Left untreated, invasive cervical cancer is almost always fatal, causing enormous 
pain and suffering for the individual and having significant adverse effects in the welfare of their 
families and communities.
A major discovery in human cancer etiology has been the recognition that cervical 
cancer is a rare consequence o f an infection by some mucosotropic types o f human 
papillomavirus (HPV).
Studies from all countries where epidemiological investigations have taken place 
indicate beyond any reasonable doubt, strong and specific associations relating HPV infections to 
cervical cancer. Studies include prevalence surveys, natural history investigations, case-control 
studies and, more recently some randomized intervention trial.3,4,5 Natural history and follow up
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studies have clearly shown that HPV infection preceded the development o f cervical cancer by 
several years and confirmed that sexual transmission is the predominant mode of HPV
• 5, 6, 7acquisition .
The primary underlying cause o f cervical cancer is infection with a high-risk type o f the 
HPV. Most new HPV infections resolve spontaneously; if  it persists, infection may lead to the 
development ofprecancer which, left untreated, can lead to cancer. As it usually takes 10-20 years 
for an HPV infection to develop into invasive cancer, most cervical cancers can be prevented by 
early detection and treatment ofHPV associated precancerous lesions, see Figure 1
1-5 years Up to 20 years
Figure 1. Natural history o f HPV infection
Experience in developed countries has shown that well planned, organized screening 
programmes with high coverage can significantly reduce the number o f new cases o f cervical 
cancer and the mortality rate associated with it. There is also evidence that general awareness 
about cervical cancer, effective screening progammes, and the improvement o f existing health 
care services can reduce the burden o f cervical cancer for women and for the health care system.
There is a difference in the incidence o f and mortality from cervical cancer between 
developed and developing countries. The main reasons for the higher incidence and mortality in 
developing countries are:
• Lack of awareness o f cervical cancer among the population, health care providers and 
policy-makers;
• Absence or poor quality o f screening programmes for precursor lesions and early-stage
11
cancer. In women who have never been screened, cancer tends to be diagnosed in its
later stages, when it is less easily treatable;
• Limited access to health care services;
• Lack o f functional referral systems.
The difference between developed and developing countries reflects strong inequalities 
in health status, and represents a challenge for health services.
Cervical cancer is rare in women under 30 years o f age and most common in women 
over 40 years, with the greatest number o f deaths usually occurring in women in their 50s and 
60s.8, 9
Over the past three decades, cervical cancer rates have fallen in most o f the developed 
world, probably as a result o f screening and treatment programs. In contrast, rates in most 
developing countries have risen or remained unchanged. Inequalities also exist in the developed 
world, where rural and poorer women are at greatest risk of invasive cervical cancer.
1.2 H um an Papillom avirus
Recently, the International Committee on the Taxonomy o f Viruses (ICTV) has 
accepted that papillomaviruses are a distinct taxonomic family, the Papillomaviridae, and are 
unrelated to the polyomaviruses and SV40.10, 11
They consist o f a 72-capsomere capsid containing the viral genome.12 The capsomeres 
are made of two structural proteins: the 57kD late protein L1, which accounts for 80% of the viral 
particle, and the 43-53kD minor capsid protein L2. HPVs are relatively stable and, because they 
have no envelope, remain infectious in a moist environment for months.13
The genome is a circular double-stranded DNA molecule consisting o f approximately 
7900 base pairs and can be divided into three regions: (1) early, encoding proteins that are 
supposed to be expressed before the onset o f viral DNA replication (2) late, encoding the viral 
capsid proteins and (3) control, which is a non-coding region14 (Figure 2). The early and late 
regions have several open reading frames (ORF) resulting in translation o f functional proteins.
The early regions ORF's (E1, E2, E4-7) are expressed early in the viral life cycle. E1 
encodes a protein that maintains the viral genome. E2 is involved in transcriptional regulation and
12
control o f the E6 and E7 genes.15, 16 The E4 gene encodes a protein that finally breaks off the 
cytoplasmic keratin networks, resulting in koilocytotic cells in the upper layers of the 
epithelium.17- 21 The E5 gene encodes a protein that is believed to boost the mitogenic responses of 
the epithelial host cells to stimulate replication o f the virus. E6 and E7 encode multifunctional 
proteins that control proliferation and transformation.17-21
The late region ORF's (L1 and L2) encode the major and minor capsid proteins o f the 
virus, repectively, which form the virus particle. The expression o f L1 and L2 is tightly bound 
with the host cell differentiation into mature keratinocytes in the upper layers o f the epithelium.22
Figure. 2. Schematic representation o f the circular HPV DNA genome.
Unlike other viruses, HPV typing is based on genomic makeup rather than antigenic 
characteristics. Currently, over one hundred types o f human papillomaviruses (HPVs) and at 
least twenty-eight types o f nonhuman PVs have been fully characterized. For a papillomavirus to 
be recognized as a distinct type, the DNA sequence o f the L1 open reading frame (ORF) o f the 
cloned genome should be no more than 90% similar to previously typed PVs.23-25
Papillomaviruses are widespread among higher vertebrates but exhibit strict species 
specificity, and transmission from non-primates to humans has not been reported. In general, they 
cause local epithelial infections, with the exception o f animal fibropapilloma viruses, where the
infection can also be found in the dermis. A viremia with viral spread to distant body sites does not
19-21, 26occur.
In vitro studies have shown that infection with HPV is an early event in the multi-step 
process o f cervical carcinogenesis. In benign and low-grade cervical lesions, the HPV genome is 
maintained in an episomal state, i.e. free in the nucleus. With the progression of CIN, HPV is
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more often found integrated in the genome o f the host cell. The integration process generally 
disrupts the E2 region and function, which will enhance the expression o f E6 and E7 because the 
E2 suppression is diminished.27 The E6 and E7 oncoproteins interfere with two pathways o f the 
cell cycle regulation. HPV E6 is able to interact with p53.19-21, 26- 29 The function of p53 includes a 
G1-phase arrest in order to allow DNA repair, and activation o f apoptosis to eliminate cells with 
damaged DNA. Interaction o f E6 with p53 leads to p53 dysfunction, thus impairing the ability to 
block the cell cycle upon DNA synthesis errors.30 In addition and independent from the p53 effect, 
E6 also induces telomerase activity preventing telomere shortening o f the chromosomes. Thus, 
E6 will keep the telomere length above its critical point and prevents cells in another way from the 
process of apoptosis.31
HPV E7 is able to effectively bind and inactivate pRb resulting in the release of the host 
transcriptional factor E2F from the pRb/E2F-complex.19, 20, 32, 33 E2F activates many genes that are 
important for mitosis, will start the cell cycle, and cause hyperproliferation.20, 34 The combination 
o f the absence o f cell cycle arrest, the absence o f apoptosis, and maintenance o f telomere length 
caused by E6, and hyperproliferation caused by E7, is considered a prerequisite for cells to 
become immortalized and obtain unrestrained growth, which may ultimately result in a
35-37malignancy.
1.3 Clinical presentation of H PV infection
Infections with HPVs may cause local cell proliferation; the majority o f these benign 
tumours regress spontaneously in immunocompetent individuals. However, persistent infections 
with high-risk HPV types have a high probability of malignancy.5, 38-39 The malignant potential o f 
HPV-induced papillomas was first demonstrated in patients with the rare hereditary disease, 
Epidermodysplasia verruciformis (EV). In these patients, several EV-specific HPV types induce 
disseminated warts. Within 20 years of disease onset, 30-60% o f EV patients are predicted to 
develop squamous cell carcinoma, primarily at sun-exposed sites. More than 90% o f these 
carcinomas contain HPV 5 DNA, and the majority ofthe remainder HPV 8 DNA.
The viral origin o f cervical cancer has now been proven beyond any reasonable doubt.5, 
40, 41 Many studies have shown that HPV DNA can be found in 99.7% of all cervical carcinomas, 
with HPV types 16, 18, 51, 45, 31 and 52 being the most frequent.38,42-44 Based on these 
observations, the anogenital HPVs have been divided into two groups: the first is associated with
14
a high risk for cervical cancer development -the HR HPVs (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 
53, 56, 58, 59, 66, 68, 73 and 82), and the second group with a low carcinogenic potential -the 
low-risk (LR) HPVs (6, 11, 40, 42, 43, 44, 54, 61, 72 and 81).38 It has been demonstrated that 
infection with a HR HPV is a necessary prerequisite for the development o f cervical cancer, and 
the World Health Organization (WHO) has recognized HPV 16 and HPV 18 as carcinogenic 
agents for humans.
1.4 H PV and Carcinogenesis
Epidemiologic information for HPV is somewhat difficult to assess because o f several 
factors: a large number o f cases are subclinical, HPV cannot be reliably grown in the laboratory45 
and it is not mandatory to report sexually transmitted HPV infections to the Centers for Disease 
Control and Prevention. Even with these caveats, dramatic rises in the prevalence of HPV 
infections have been reported46 and o f the sexually transmitted viruses, HPV is known to be the 
most common.44 In regard to sexually transmitted diseases as a whole, HPV infection was found 
to be more common than infections with Neisseria gonorrhoeae, Chlamydia trachomatis, or than 
mucopurulent cervicitis.
As stated previously, there are more than 200 types o f HPV, all o f which infect the 
squamous epithelia o f the skin and mucous membranes. Certain HPV types show preference for 
infecting the cutaneous epithelium. This group is found in deep plantar warts, common warts, flat 
warts and Bowen's disease (a variant o f squamous cell carcinoma in situ).11, 12
Other types o f HPV show predilection for the mucous membranes of the anogenital 
region. The most common sites for infection in men are the penis, perianal region, perineum, and 
scrotum; and in women are the vaginal introitus, vulva, cervix, perineum, and perianal region.47
Genital HPV infections are sexually transmitted and HPV cannot be normally detected 
in the cervix o f virgins.44 If  women are closely followed with HPV detection and cervical scrapes 
after the onset o f sexual intercourse, about 50% will be infected with genital HPV within 2 years 
o f the onset o f sexual intercourse.44, 48, 49 It is estimated that the lifetime risk o f contracting a genital 
HPV infection is 80%, from which, less than 1% will progress to invasive carcinoma.44, 48,50 Most 
HPV infections and low-grade CIN lesions will disappear within 8 months after the first
44, 51-54exposition.
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In women with normal cervical scrapes, the point prevalence o f any HPV type is age- 
dependent, varying from 20% in women aged between 20-25 years, to 6% in women older than 
30 years.55 Some studies have shown a second peak in HPV point prevalence in women above the 
age of 55.56-59 Other studies have shown a cumulative prevalence o f high-risk HPV (hr-HPV) 
infections ofup to 70% with sequential cervical scrapes, even with one menstrual cycle.54, 60-62
In CIN lesions both low- and high-risk mucosal HPV genotypes have been detected. 
Low risk HPV genotypes, like HPV 6, 11, 40, 42, 43 and 44, are predominantly present in 
condylomata accuminata, ASCUS and CIN 1. Hr-HPV genotypes are often detected in CIN 2 and
3 and in invasive cancer.5, 63
The prevalence o f hr-HPV genotypes rises with increasing severity o f the CIN lesion but 
depends also on the detection method.64 HPV tests using polymerase chain reactions (PCR) have 
proven to be more sensitive in detecting hr-HPV genotypes than in situ hybridization tests, like 
Hybrid Capture II. The use of consensus assays allows detection o f a broad range o f HPV types. 
Primers are designed to target conserved regions among different genotypes. The L1 region is not 
only highly conserved; it is used in the formal classification of HPV types because o f sequence 
relatedness. The most commonly used primers target the L1 region. Initially, degenerate primer 
pairs were used (MY09/11). Use of oligonucleotides containing degeneracies can result in a lack 
o f reproducibility and high variation between PCR runs. These have now been replaced with a set 
o f oligonucleotide pools obtained by grouping virus types together by sequence homology over 
the same MY09/11 primer regions. This results in 5 upstream oligonucleotides for the PGMY11 
primer pool and a set o f 13 downstream oligonucleotides for the PGMY09 primer pool. This 
primer set amplifies a 450-base pair (bp) fragment. The GP5+/6+ primer set amplify a 150-bp 
fragment o f the L1 region. With the implementation o f these sensitive general PCR primers such 
as MY 11/09 and GP5+/6+ up to 99% o f cervical cancers were hr-HPV positive.65 To detect the 
exact HPV genotype, type specific primers are available, but type specific detection requires an 
elaborate laboratory procedure, especially when multiple genotypes are present. With the 
introduction o f a short fragment polymerase chain reaction in combination with reverse 
hybridization in a line probe assay (SPF10 LiPA PCR), it became possible to detect and 
subsequently simultaneously type 25 different high- and low-risk HPV genotypes in a two step 
process.66-69 This HPV detection method has been technically validated and proved to be highly 
sensitive, specific and reproducible.66-71 With this assay, hr-HPV was shown to be present in 51% 
o f patients with ASCUS scrapes, 78% o f patients with CIN 1, 86% o f patients with CIN 2 and
16
88% ofpatients with CIN 3.66
Roche Diagnostics developed the Amplicor HPV test, which is a PCR assay that uses L1 
consensus biotinylated primers (165-bp product) and the Linear Array line blot hybridization 
with immobilized probes. The Amplicor HPV test can determine the presence of 13 individual 
high-risk DNA genotypes (Future versions will expand that to 37 high- and low-risk types.) and 
the human beta-globin gene as a positive control.
All these clinical applications underline the need for using a reproducible genotyping 
method with an adequate sensitivity and specificity.
Detection of hr-HPV genotypes in normal cervical scrapes has been associated with an 
increased risk o f developing CIN.72 However, especially young women often have transient 
infections, and more than 80% o f all HPV infections will be cleared.54, 63, 66, 73-76 Several reports have 
shown that women with hr-HPV positive CIN lesions were more likely to progress than women 
with hr-HPV negative CIN lesions, and therefore, progression o f CIN lesions is assumed to be 
associated with a persistent hr-HPV infection.77, 78 Later it was shown that patients with persistent 
hr-HPV infections have a 100-300 fold increased risk for development o f a CIN 3 lesion,79-83 while 
clearance o f HPV from the uterine cervix was associated with regression o f the CIN lesion.84
Many studies have investigated the addition o f HPV detection in cervical scrapes to 
conventional cytology in cervical cancer screening, in order to improve its sensitivity and 
specificity in detecting high-grade CIN.85-90 A consensus meeting in the United States concluded 
that only in women with ASCUS scrapes, additional HPV detection increases the sensitivity of 
the screening.91
1.5 Situation of cervical cancer in the Am ericas
Cervical cancer occurs worldwide, but the highest incidence rates are found in Central 
and South America, The Caribbean, Eastern Africa, South and South-East Asia, and Melanesia.92 
There are an estimated 27,500 deaths each year in the Americas from cervical cancer. Globally 
cervical cancer has been estimated to account for 2.1% o f deaths among women aged 25-64 but in 
Latin America it accounts for 3.8% ofthese deaths.93
It is a disease o f inequities which disproportionately affects women from vulnerable and 
disadvantaged groups such as indigenous women, women residing in rural areas, and sex
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workers. There are geographic contrasts in the distribution o f the disease as well, and cervical 
cancer mortality rates are seven times greater in Latin America and the Caribbean (LAC) than in 
the United States and Canada. As illustrated in figure 3, Bolivia, Haiti and Nicaragua are among 
the countries with the highest cervical cancer rates.
Figure 3. Cervical cancer incidence rates in North, Central, South America and the Carribean.
In the Americas, cytology screening (Pap test) has been in place for over 30 years, either 
through opportunist screening or through organized screening programs. Yet, countries in LAC 
have not experienced the same declines in mortality rates as those observed in North America. 
Few countries in the region, such as Chile, Costa Rica, and Mexico have observed reductions 
between 20 and 30% in cervical cancer rates, which have been attributed to improvements in the 
coverage, organization and quality o f their screening programs.94 It has proven to be difficult to 
mount and sustain high quality screening programs in low resources settings.
In many countries, although cervical cancer screening is being performed, the various 
parts o f a cancer control program is not fully integrated or well coordinated either within or 
between the public or private health sectors so as to create an efficient and effective program. 
Many countries do not have adequate information systems for the effective management of
18
cervical cancer prevention programs. The absence of such systems precludes effective patient 
follow-up and management, ongoing assessment o f coverage, and determination o f a program's 
effectiveness through ongoing evaluation and cervical cancer remains a major public health 
problem.
1.6 Cervical cancer in H onduras
According to the National Cancer Registry, there were 4390 cases o f cancer among 
women in 2004. Annually there are 3966 deaths from cancer in the country, from which 68% are 
female and 32% are male. Approximately 1600 cases o f cervical cancer are diagnosed each year; 
being the woman between 40-44 years the most affected.
In the year 2000, estimates o f the age standardized incidence and mortality rate of 
cervical cancer in Honduras were 30.6 cases per 100,000 and 15 per 100,000 inhabitants 
respectively.95 Universally agreed upon risk factors for cervical cancer include HPV, having 
multiple sexual partners (or a partner who has multiple partners), early age at first intercourse a 
history o f sexually transmitted diseases, low socioeconomic or educational status and
i • 96 99smoking.
Research in Honduras suggests that exposure to wood smoke in the kitchens is also a risk 
factor for invasive cervical cancer, independent o f other factors such as education, parity and 
number o f sexual partners.99 Methods proposed to mitigate some o f these independent risk factors 
were examined in a meta-analysis o f studies in the developing world as well as in a case-control 
study in Honduras.100-103 The studies demonstrate education to be especially important in 
empowering women to foster lifestyles that result in decreased risk for cervical cancer. Thus, 
poor, less educated women are disproportionately affected in terms o f both incidence and 
mortality.103,104 Although the importance of HPV infection is not universally recognized by 
providers throughout the country, a case-control study in Honduras found that HPV 16 and 18 are 
associated with 95% o f invasive cancers.104
WHO currently recommends Pap screening as the screening methodology o f choice 
when resources allow it. The Ministerio de Salud Publica (National Ministry o f Health) 
recommends that women who are sexually active get a Pap smear every three years, especially 
once they are over thirty years old. Currently, screening exams are mostly carried out in public 
and private clinics throughout the country although services are clustered around more urban
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areas with infrequent “brigades” offering services in more remote rural areas. In a Honduran 
national health survey published in 2001, 60.9% o f sexually active women aged 15-49, were 
found to have ever had a Pap smear (Ministerio de Salud Publica Nacional, USAID, CDC, 
PAHO. Encuesta nacional de epidemiologia y salud familiar 2001).105
Follow-up is a major weakness o f the current Honduran prevention program. Despite a 
moderate amount o f adherence to screening recommendations, women report never receiving 
their results and clearly lack a very basic understanding o f what the results mean when they do 
receive them (Ministerio de Salud Publica Nacional, USAID, CDC, PAHO. Encuesta nacional de 
epidemiologia y salud familiar 2001).105
The critical link between screening and follow-up treatment is the delivery o f Pap 
results, and this link is requisite to the realization of any effect from increased screening efforts. 
Moreover a program's effects may only be maximized when the delivery o f results is coupled 
w ith counseling for any follow-up necessary and a strategy designed for these women to access 
follow-up services, including creative approaches to financing care, is in place.106
1.7 Aim and outline of this thesis
Due to the widespread nature o f infection, HPV-induced malignancies remain a major 
public health issue through the world, mainly in Developing countries. Honduras is a country 
w ith a high incidence o f cervical cancer, where vaccination campaigns could benefit a large 
proportion o f Honduran women in risk for this disease and where a comprehensive program to 
transform a prevention strategy into appropriate, accessible and applied practices is needed.
We engaged with this thesis, in order to originate a baseline for these purposes to 
investigate the prevalence, type distribution o f HPV, molecular variants o f HPV 16 and co-factors 
involved in the process o f carcinogenesis o f HPV infections in Honduran women. C hap ter 2 
describes a prevalence study o f HPV infection in Honduran women with normal cytology and the 
distribution o f individual HPV types in this group of women.
One o f the main issues o f the thesis was to identify epidemiological co-factors which 
contribute, besides HPV, to the development o f cervical cancer; these are discussed in C hap ter 3.
In the initial phase o f the study, we started with a research to the prevalence in female 
university students in Honduras o f HPV and C. trachomatis, which is the most common sexually
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transmitted bacterial infection in the world and sexually active young persons are at highest risk, 
this is described in C hap ter 4.
C hap ter 5 reports the prevalence o f HPV in female university students o f Tegucigalpa, 
Honduras using the Linear Array from ROCHE, that enables PCR-based identification of 37 
high- and low-risk HPV genotypes, including those considered a significant risk factor for 
progression to cervical cancer.
Besides the importance of specific HPV genotypes, other viral cofactors as viral load 
may influence the progression likelihood. In C hap ter 6 the relationship between HPV 16 viral 
loads with respect to the grade o f cervical disease in Honduran women was investigated.
In C hap ter 7 the prevalence o f HPV 16 variants in Honduran women with normal 
cytology and with dysplasia and cervical cancer using a novel reverse hybridization assay (LiPA) 
in order to determine if  there is any association among HPV 16 variants and the severity of the 
disease is reported. And finally in C hap ter 8, future directions are discussed in general, based on 
the results of the studies presented in this thesis.
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Abstract
Objective. This study was aimed at estimating type-specific HPV prevalence and its cofactors 
among Honduran women with normal cytology in order to provide valuable information to health 
policymakers about the epidemiology of this important sexually transmitted infection.
Methods. A total of 591 women with normal cytology from Tegucigalpa, Honduras were 
interviewed and tested for HPV using the SPF10 LiPA25. A structured epidemiological 
questionnaire was administered to each woman.
Results. The overall HPV prevalence was 51%. Twenty-three types of HPV were detected; HPV 
16,51,31,18 and 11 were the most common. The highest prevalence of cancer associated HPV 
types (15.0%) was found in the women less than 35 years. Besides the association with age, the 
main independent predictors of HPV infection were the lifetime number of sexual partners and 
having a low socioeconomic status (SES) and less than 5 previous Pap smears.
Conclusions. In the population studied, there was a broad diversity of HPV infections, with high­
risk types being the most common types detected. The establishment of a well-characterized 
population with regard to the community prevalence of type-specific HPV infection will provide 
a valuable baseline for monitoring population effectiveness of an HPV vaccine.
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Introduction
Carcinoma of the cervix is the most common type of cancer in the developing world and 
the leading cause of death from cancer among women. The estimated new cervical cancer cases 
per year is 500,000,1 80% of which is occurring in the developing countries.2 In Central and 
South America, the incidence rate is about 5 times as high as in Western Europe.3 In Honduras 
cancer of the cervix is a major public health problem and also has the highest mortality rates due 
to cancer among women with a cervical cancer age standardized rate of 30.6/100,000 
inhabitants.4
There is overwhelming data from multiple epidemiologic and laboratory studies 
demonstrating the central etiologic role of human papillomavirus (HPV) in cervical cancer.5'6’7,8'9,10
It is necessary to understand the global burden of HPV infections in order to establish 
effective prevention strategies such as improved screening programs, public health education 
and vaccines." In this context, surveys to determine HPV prevalence in different age groups and 
circulating genotypes in the population are needed to understand the wide variations in the 
incidence of cervical cancer in populations worldwide. These will contribute to establish the 
proportion of women that could be effectively protected by vaccination.
Despite the high incidence of cervical cancer reported from Honduras, population based 
studies on the HPV prevalence and genotype distribution are scarce.12,13 It is of fundamental 
importance to get insight into the development of this disease in order to design effective 
strategies to treat and prevent cervical carcinoma and its related mortality and morbidity.
This study was aimed at determining type-specific HPV prevalence and its cofactors 
among Honduran women with normal cytology in order to provide valuable information to health 
policymakers about the epidemiology of this sexually transmitted infection.
Materials and methods
Study population and collection o f specimens
The study population included a sample of 591 women, randomly selected, attending a 
communal cervical cancer screening centers and family planning clinics in lowmedium 
socioeconomic settings in Tegucigalpa, the capital city of Honduras. In general, women may be 
referred for screening by their physicians or request screening on their own accord. Eligible 
women were those between 18 and 65 years of age, identified as being resident for at least 6 
months in Tegucigalpa, without a history of preneoplasic or neoplasic lesions of the cervix, 
conization or hysterectomy, not currently pregnant, who were willing to participate and who 
signed an informed consent form. The nature of the study was explained to the patients by trained 
medical staff.
A thorough physical examination was performed, and a structured epidemiological 
questionnaire was administered to each woman. Questions pertained to sociodemographic 
variables like age, occupation, education level, smoking, contraceptive use, previous cervical 
smear history and exposure to wood smoke and also questions regarding sexual behavior to gain 
insight into risk factors for acquiring HPV were asked. The interviews lasted approximately 15 
min. Assurance of confidentiality was obtained by gathering some of the information in two 
different questions and at the end of each interview the interviewer could address if the 
information given by the patient was reliable and if she appeared confident.
The study was reviewed and approved by the correspondent ethical committee.
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Five women did no consent to participate in the study (< 1 %)
An Ayre spatula was used to obtain a cervical smear, which was immediately fixed for 
cytological examination. Following the Pap collection, additional material was obtained from 
the cervix for HPV analysis and placed in 5 mL sterile phosphate-buffered saline (PBS, 0.82% 
(w/v); NaCl, 0.19% (w/v); NajHPO^HjO, 0.03% (w/v); NaH2P042H20 , adjusted to pH 7.4 with 
HCL1M) 0.005% thimerosal. Upon arrival in the laboratory, cells were vortexed, centrifuged for 
10 min at 4,500 rpm, then resuspended in 1 mL of PBS and centrifuged again for 10 min at 4,500 
rpm, resuspended in 0.5 mL of PBS and stored at -20C for further analysis. Extreme caution was 
taken to prevent crosscontamination of specimens. Pap smears were all reviewed by the same 
pathologist. Six women were excluded due to abnormal cytology results (1 %).
HPVDNA detection
DNA extraction andHPV-PCR assay
DNA extraction from the cervical cells was performed according to the Boom method 
as previously described.14 Two hundred microliters of material was isolated and resuspended in a 
final volume of 100 jxL; an extraction control consisting of nuclease free water was placed after 
every 5th sample. About IOjxL of sample DNA or control were used for each of the various PCR 
analyses.
All samples were prescreened with the fi-globin primers PC03/PC05 to assess sample integrity. 
All work was performed in a laminar flow hood in a dedicated room free from plasmid DNA.
HP VSPFI0 Line Blot25 assay
(i) PCR amplification o f HPV DNA
Broad-spectrum HPV DNA amplification was performed using a short PCR fragment 
assay (HPV SPF10 Line Blot^ assay Labo Biomedical products B. V. Rijswijk, The Netherlands). 
This assay amplifies a 65-bp fragment of the LI open reading frame, and allows detection of at 
least 43 different HPV types. SPF10 PCR system was performed in a final reaction volume of 50 
(iL, containing 10 pL of the isolated DNA sample and 40 (iL PCR mix, containing 10 mmol/L 
Tris- HCL (pH 9.0), 50 mmol/L KCL, 2.0 mmol/L MgC12,0.1% Triton X-100,0.01% gelatine, 
200 |a,mol/L of each deoxynucleoside triphosphate (dATP, dCTP, dGTP, and dTTP), 15 pmol each 
of the forward and reverse primers tagged with biotin at the 5 ’ end, and 1.5 units of AmpliTaq 
Gold (Applied Biosystems, Foster City, CA, USA). Activation of AmpliTaq Gold for 9 min at 
94°C was followed by 40 cycles of 30 s at 94°C, 45 s at 52°C and 45 s at 72°C, with a fmal 
extension of 5 min at 72°C. Appropriate negative and positive controls were used to monitor the 
performance of the PCR method in each experiment. To avoid contamination by PCR products, 
sample preparation and the amplification reaction were all performed in separate rooms.
(ii) HPVdetection byDEIA
The presence of HPV DNA was determined by hybridization of SPF10 amplimers to a 
mixture of general HPV probes recognizing a broad range of high-risk, low-risk and possible 
high-risk HPV genotypes in a microtiter plate format, as described previously. All HPV DNA 
positive samples (by SPF10 DEIA) were genotyped using the HPV SPF10 Line Blot^ genotyping 
assays.
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(iii) HPVgenotyping by reverse hybridization using theHPVSPF10LineBlot25genotypingsystem
The 28 oligonucleotide probes which recognize 25 different types were tailed with 
poly(dT) and immobilized as parallel lines to membrane strips (Labo Bio-medical products B. V. 
Rijswijk, The Netherlands). The HPV genotyping assay was performed as described previously. 
The LiPA strips were manually interpreted using the provided reference guide.
The samples that tested positive using the DNA Enzyme Immuno Assay but showed no 
results on the LiPA strip were considered to be HPV X-type, i.e., genotypes not present on the 
LiPA strip.
To evaluate performance and reproducibility of the analysis, a quality control program 
from DDL was performed.
Data analysis
Statistical analyses were performed using the programs Epilnfo 6.02 (CDC) statistical 
program, Excell and LogXact version 4 (Cytel, Cambridge Ma).
Univariate statistics were calculated for all variables. Any p  value less than 0.05 was 
considered significant. Odds ratios (ORs) and 95% confidence intervals (CIs) were obtained 
from multiple logistic regression models to evaluate the association between HPV infections and 
risk factors. Variables found to be significantly related to HPV infection by univariate analyses 
were entered into a multiple logistic regression model. We adjusted for age using five groups 
contrasted as dummy variables (18-24,25-34,35-44,45-54, and 55-65) and for HPV infection 
status (only low risk types and any high risk types). We investigated the potential association with 
education, socioeconomic status, exposure to wood smoke, history of pregnancy, parity, age at 
first intercourse, lifetime number of sexual partners, number of previous screens, time since last 
Pap smear, history of sexually transmitted diseases, and occurrence of other genital infections 
that could influence the development of SIL. The variables that remained in the final multivariate 
models were: age, women’s education, socioeconomic status, time since last Pap smear, and 
number of sexual partners.
Results
Among the 591 women with normal cytology enrolled in this study, 29 were negative for 
the P-globin PCR and were eliminated from the study; from the remaining 562 samples, 289 
(51 %) were positive for HPV DNA. Overall, single genotypes were found in 67% of the 289 HPV 
positive women (36% of the entire sample) and multiple genotypes were detected in 33% of the 
HPV positives women (15.8% oftotal).
Figurel. Prevalence 
of individual HPV 
types among Honduran 
women with normal 
cytology.
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Twenty-three HPV types were ascertained; HPV 16 (25%), HPV 18 (12%), HPV 51 
(10%),HPV31 (8%)andHPV 11 (8%) were the most common types identified (Figure 1).
Figure 2 shows the age-specific prevalence of HPV detection. HPV DNA was detected 
in 58% of women aged less than 25 years, with prevalence decreasing in older women to a 
minimum of 30% among women older than 55.
Overall of the 51% HPV positive women, 35.7% were infected with high risk (HR) 
types and 15.3% with low risk (LR) types only. Women who were infected with both HR/LR 
types were grouped as HR types. HR HPV age-specific prevalence was highest among women 
below age 25 (46.5%), and again lowest among women aged 55 or more years (22.7%) (Figure 3).
When considering all HPV types and all age groups combined, besides the association 
with age, we observed a trend for HPV infection and the lifetime number of sexual partners (Table 
1). The only other factors that remained significant were having a low socioeconomic status 
(SES) and less than 5 previous Pap smears, and women who had 6 or more previous screens had a 
reduced risk of HPV infection. In HPV positive women, risk factors for detection of single and 
multiple HPV infections for all types were analyzed (Table 2). A total of200 (69%) o f289 HPV- 
positive women had a single infection, whereas 89 women (31%) had multiple HPV type 
detected. For single HPV infection, the highest prevalence was found among women less than 25 
years (48.8%), whereas for multiple infections the highest percentage was observed in women 
between 25 and 34 years (19.3%). Both single and multiple infections were associated with low 
socioeconomic status (SES) and with reporting more than one lifetime sexual partner. When 
analyzing the number of previous screens, an OR of 1.9, for women who had undergone 
cytological screening 6-10 month prior to the interview, was observed. A stronger association 
was found in the women with multiple HPV infection that had the last Pap smear taken 0-5 
months before (OR=2.6).
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When doing multivariate logistic regression analysis, a statistically significant 
association for HPV infection was ascertained for the women who had a low SES (OR=l .8,95% 
CI=1.2-2.5).
Risk of HPV infection was reduced for women who were 45 years or older and had only 
one lifetime sexual partner (QR=0.7,95%CI=0.5-1.0).
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Table 1 R isk factors for H P V  D N A  detection among Honduran asym ptomatic women
2
HPV positive (289) Low-risk HPV types High-risk HPV types
Age (years) 
< 25  
25-34 
35—44 
45-54 
> 55
4.4
16.9
16.9
10.9 
2.3
W om en’s education (years)
> 7  19
< 7  32
Socioeconomic status
Medium 15.1
Low 35.6
Exposure to wood smoke 
No 18.0
Yes 35.2
Parity
0-3 33.7
> 4  19.1
Age at firs intercourse 
> 18  22 
<18 31
Lifetime number of sexual partners 
1 23.7
> 1  29.4
History of oral contraceptive use 
No 17.6
Yes 32.7
No. previous screens
> 10 6.2 
6-10 17.8
0-5 29.2
Time since last Pap smear (months) 
0-11 40
>12 13.2
3.31
2.80
2.94
2.20
1.00
1.00
1.05 (0.78-1.41) 
1.00
1.28 (0.88-1.85) 
1.00
0.79 (0.53-1.16) 
1.00
0.72 (0.50-1.05) 
1.00
0.95 (0.66-1.36) 
1.00
1.33 (0.93-1.90) 
1.00
1.05 (0.73-1.52)
1.00
1.04
1.42
1.00
0.94 (0.61-1.43)
0.2
1.8
1.9
1.8
0.4
4.7
7.3
4.6
6.6
5.7
6.4
7.8
4.8
6.0
6.0
6.7
5.3
5.2
9.2
2.5
4.4
5.5
7.9
4.5
0.86
1.91
2.21
2.35
1.00
1.00
0.99 (0.53-1.85) 
1.00
0.78 (0.35-1.71) 
1.00
0.45 (0.21-0.99) 
1.00
0.79 (0.35-1.74) 
1.00
0.67 (0.31-1.45) 
1.00
0.85 (0.39-1.84) 
1.00
2.20 (1.01—4.79)
1.00
0.62
0.64
1.00
1.62 (0.70-3.70)
3.6
11.4
12.3 
7.1 
1.8
15.8
27.0
10.8 
30.7
13.5
30.6
26.7
17.8
16.0
27.3
28.3 
13.5
3.5
14.2
26.2
10.4 
33.0
3.44
2.45 
2.78 
1.88 
1.00
1.00
1.08 (0.78-1.49) 
1.00
1.54 (1.01-2.37) 
1.00
0.91 (0.59-1.40) 
1.00
0.84 (0.56-1.27) 
1.00
1.14 (0.76-1.71) 
1.00
1.35 (0.91-2.00) 
1.00
0.93 (0.62-1.41)
1.00
1.47
2.27
1.00
0.88 (0.55-1.42)
Table 2 Risk factors for HPV DNA single and multiple detection among Honduran asymptomatic women
HPV single detection («—183) HPV multiple detection ( n—93)
% OR % OR
Age (years)
< 2 5 7.4 5.74 1.5 0.98
25-34 19.5 3.38 12.5 1.86
35—44 23.2 4.23 9.6 1.50
45-54 15.1 3.21 6.6 1.21
> 55 2.2 1.00 2.6 1.00
Women’s education (years)
>7 15 1.00 9.0 1.00
< 7 25.5 1.07 (0.77-1.49) 16.4 1.14 (0.75-1.75)
Socioeconomic status
Medium 10.6 1.00 8.0 1.00
Low 28.6 1.47 (0.95-2.28) 17.2 1.16 (0.68-1.99)
Exposure to wood smoke
No 14.6 1.00 8.2 1.00
Yes 27.1 0.74 (0.48-1.15) 18.8 0.92 (0.53-1.60)
Parity
0-3 26.2 1.00 16.1 1.00
> 4 16.0 0.78 (0.51-1.19) 11.5 0.90 (0.54-1.53)
Age at firs intercourse
> 18 18.0 1.00 9.8 1.00
<18 23.6 0.88 (0.58-1.33) 16.9 1.16 (0.68-1.96)
Lifetime number of sexual partners
1 19.0 1.00 11.4 1.00
> 1 22.5 1.27 (0.85-1.91) 15.5 1.46 (0.88-2.44)
History of oral contraceptive use
No 24.3 1.00 17.0 1.00
Yes 15.0 1.20 (0.79-1.82) 8.2 0.95 (0.55-1.61)
No. previous screens
> 1 0 9.2 1.00 2.3 1.00
6-10 21.8 0.86 11.9 1.87
0-5 34.9 1.14 19.9 2.61
Time since last Pap smear (months)
0-11 31.0 1.00 20.8 1.00
>12 10.5 0.96 (0.59-1.55) 6.5 0.89 (0.48-1.63)
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Discussion
In our survey, the prevalence of genital HPV infections in the studied population was 
very high (51%) when compared to what has been reported internationally. It is higher than the 
prevalence found among women with normal cytology in several other Latin American 
countries: Costa Rica (16%), Mexico (14.5%), Colombia (14.9%) and Chile (14.0%) but similar 
to the one observed previously in Honduras (39%) considering that in the present study a more 
sensitive PCR detection system was used.131518
As it happens in most developing countries, in Honduras some cultural factors can be 
related to this high HPV prevalence, especially lack of education, early start of sexual activity, 
multiparity, and the prevalence of attitudes, misconceptions and beliefs that constrain people 
from discussing diseases of the genital tract. In most developing countries, access to health 
services is limited and screening for cervical cancer either is non-existent or reaches few of the 
women who need it. A well functioning health system, with the necessary equipment and trained 
providers, is essential for prevention activities, screening and diagnosis, linkages for follow-up 
and treatment, and palliative care.7'9'10'12'13'15
Twenty-three different HPV types were detected in women in this study, which 
confirmed that there is great variability in the range of HPV types detected in exfoliated cervical 
cells at a population level in Latin America.15,19,20
As was seen in previous studies examining prevalence of various HPV types among 
large numbers of women presenting for reasons other than cervical neoplasia or known 
gynecologic problems, we found HPV 16 to be the most frequently detected HPV type, followed 
by HPV 18, HPV 51 and HPV 31.16'21'22 In a Colombian-based study, HPV 16 was followed by 
HPV 58, 56, 18 and 51.17 In studies of Dutch, Mexican and British women, the second most 
frequently HPV type detected was HPV 31, whereas among Brazilian women and women in the 
United States, HPV 53 was detected most frequently after HPV 16.21 In the Costa Rican 
population oncogenic types 58, 51, and 52 were also relatively abundant, followed by types 31 
and 18.15 It seems that the family of HPV 50s is common in Latin America and should be 
considered when developing HPV vaccines tailored to this population.
A slightly higher prevalence of infection was found in women less than 25 years, with a 
strong predominance of cancer-associated HPV types and single HPV infections. HPV detection 
decreases among the women over 55 years (Figure 2). This result has been interpreted as an 
indicator of the sexual transmission as it coincides with the initiation of sexual activity. It is a 
known fact that HPV prevalence decreases with age, as has been shown in several studies of 
younger women.23'25
We did not find a second peak of HPV after 5 5 years of age as observed in a cohort study 
being conducted in Guanacaste, Costa Rica15 and in Morelos, Mexico.16 Our results are well in 
accordance with Cuschiere et-al,26 who did not find a second peak in peri-menopausal women in a 
survey conducted in Edinburgh and with Beby-Defaux et-al27 in women who attended a Health 
Examination Center of the French social security; they observed that HPV prevalence gradually 
decreased with age. Differences in HPV DNA prevalence found in different studies, overall and 
by age, may be partly accounted for by differences in cohort effects and PCR methods used for 
HPV detection. In our study, it could also be that the group of women over 5 5 years was too small 
(13 women) to exhibit a second peak.
The presence of multiple infections (33%) was higher than previously observed among 
control subjects in the IARC studies done in the Philipines (14.3%),28 Thailand (9.8%),29 Moroco 
(5.3%),30 Paraguay (16.7%)22 and The Netherlands (28%),21 but lower than in a population-based 
study from Costa Rica (39%)15 and similar to the results from a study done in Colombia (29.7%).17 
The extent and importance of multiple HR-HPV infections in the progression of cervical 
neoplasia and its management remain unknown. Some studies have described multiple HR-HPV 
infections to be most prevalent in young women and to be more frequent in low grade than in high
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grade cervical neoplasia, which could reflect common sexual transmission of multiple HR- 
HPV.22’26'31'32 On the other hand, Bachtiary et-al,33 demonstrated that the presence of multiple HPV 
types is associated with poor response and with reduced survival in cervical cancer patients who 
receive radiotherapy as the primary treatment.
We explored risk factors for acquiring HPV infection and found that the number of 
sexual partners was weakly related to HPV infection, in contrast to what has been demonstrated 
in previous studies34'35,36 and not well in accordance with data described before in Honduran 
women.37 This could be the result of bias, since for cultural reasons women might not tell the real 
number of sexual partners or it could be explained by the predominance of “male role” in the 
transmission of HPV infections to women committed to one sexual partner. In this context, a 
woman's risk of cervical cancer may depend less on her own sexual behavior than on that of her 
husband or other male partners. Unfortunately, no information was available on the sexual 
behavior of the partners in our study population.
In the present study there was no association between HPV infection and the use of 
wood for cooking, considering that bias could have been introduced when they answered the 
question and the time of exposure to wood smoke was not measured. On the other hand, Ferrera et 
al. found in a case-control study performed in Honduran women, a strong association between 
the use of wood as cooking fuel for many years and cervical cancer even after adjustment for 
education, strongly suggesting that exposure to wood smoke is not just an indicator of SES, but 
inclined them to believe that there could be a biologic effect.
Our results also showed that there was an association of HPV infection with number of 
previous screens, especially for multiple infections, in which women who had less than 5 
previous screens had a two times higher risk of HPV infection than women who had more than 10 
previous screens, supporting the preponderant role of cervical screening in the effective control 
of cervical cancer. This is in complete concordance with previous findings in Honduran women 
in a case-control study; cytological screening conferred a protective effect.13 Prospective studies 
are required to assess the impact of multiple HR-HPV infections on neoplastic progression.
There are limitations in the design of the study; one of them is the small sample size, 
especially in women over 55 years of age. As a health care center-based study, there is a potential 
bias related to the selection of the study subjects, as they were primarily seeking cervical cancer 
screening services. It would be necessary to compare some of the variables, like the education 
level of women participating in the study with women in the general population to see how 
representative the sample of women participating in the study is of the general population.
The recent approval by the US FDA and the European EMEA of an HPV vaccine to 
prevent high-risk HPV infection and development of cervical cancer represents a major 
landmark to eliminate the suffering and death due to cancer, reduce the need for costly medical 
procedures and provide both women and communities throughout the world with substantial 
benefits. HPV 16-18 vaccination will prevent HPV 16-18 incident infection, and subsequently 
decrease in 90% the frequency of abnormal Pap attributable to these types and in about 50% 
overall abnormal Pap.38 Besides, HPV vaccination will reduce the number of women who require 
colposcopy, biopsy, and cervical treatment for precancerous cervical lesions.39
To maximize the cost-effectiveness of a HPV vaccination programmes, it is important 
to understand the distribution of the major HPV types in various geographic regions. The results 
emanating from this research may assist the public health authorities in planning prophylactic 
and therapeutic strategies to prevent cervical cancer, including HPV diagnosis and rational 
vaccine strategies. The establishment of a well-characterized population with regard to the 
community prevalence of type-specific HPV infection will provide a valuable baseline for 
monitoring population effectiveness of an HPV vaccine.
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Abstract
Objective. The aims of this study were to investigate HPV genotypes in women with cervical 
intraepithelial lesions and cervical cancer in Honduras, and to identify epidemiological cofactors 
that contribute to the development of cervical cancer.
Methods. 289 cases were analyzed, 139 with LSIL, 60 with HSIL, and 90 with CC using the HPV 
SPF10 Line Blot assay.
Results. HPV DNA was detected in 81% of LSIL 97% of HSIL and 93% of women with CC. HPV 
16 was detected in 41% of CC, 35% of HSIL, and 24% of LSIL. HPV 18 was found in 9% of CC, 
in 4% ofHSIL, and 5% ofthe women with LSIL.
Conclusion. The implementation of the prophylactic vaccines against HPV genotypes 16 and 18 
has the potential of preventing at least a quarter of LSIL, one third of HSIL and about half of 
cervical cancer cases in Honduras.
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Introduction
Latin American countries, together with Sub-Saharan Africa, South, and South East 
Asian countries, are the regions of the world with highest incidence of cervical cancer (CC).1
Honduras is, no exception and cancer of the cervix is a major public health problem, 
with the highest mortality rates from cancer among women (ASR o f30.6/100,000 inhabitants) in 
the country.
Although the causal role of high risk (hr) HPV infection in the cervical cancer and its 
precursors (SILs) has been established,2 the mechanisms by which HPV induces cancer and the 
molecular genetics ofthe process continue to be active areas ofresearch.
HPV infection is mostly a transient infection not resulting in cervical lesion or leading to 
low-grade lesions that often regress spontaneously.3 However, an estimated 3 to 10% of women in 
different populations cannot clear the viral infection and become persistent HPV carriers, 
constituting a high-risk group for progression to CC.4
The study of HPV genotypes distribution in women with CC is essential for predicting 
the potential worldwide effect of new prophylactic vaccines against HPV-16 and HPV-18, as well 
as in determining the priorities for the inclusion of HPV types in future HPV vaccines and HPV- 
based screening tests. 5,6
Studies on the prevalence of HPV infection in Honduras are needed, because 
information on hrHPV prevalence is limited. The aims of this study were to investigate HPV 
genotypes in women with cervical intraepithelial lesions and CC in Honduras and to identify 
epidemiological cofactors that contribute, to the development of CC.
M aterials and methods
Study population and collection o f  specimens
The study population included a sample of 289 women, aged 19 to 67 years, attending 
the San Felipe General Hospital, a referral center for cancer patients in low to medium 
socioeconomic settings in Tegucigalpa, Honduras.
Eligible women were those with histological verified CIN or invasive cancer (IC) and 
identified as being resident for at least 6 months in Tegucigalpa or in a 150 km radius of the city 
who were willing to participate and who signed an informed consent form. A thorough physical 
examination was performed, and a structured epidemiological questionnaire was administered to 
each woman. Emphasis was given to lifetime sexual behavior, reproductive history, history of 
cytologic screening, use of contraceptive methods, and several demographic data.
Patient evaluation included a Pap smear, colposcopic inspection of the cervix and a 
cervical biopsy. The histologic finding based on the biopsy decided the final classification of each 
case in the study. All histologic slides were read by a single experienced pathologist. The study
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was reviewed and approved by the correspondent ethical committee.
An Ayre spatula was used to obtain a cervical smear, which was immediately fixed for 
cytologic examination. After Pap smear collection, additional material was obtained from the 
cervix for HPV analysis and placed in 5 mL sterile phosphate-buffered saline (PBS) with 0.005% 
thimerosal. On arrival in the laboratory, cells were vortexed, centrifuged for 10 min at 4,500 rpm, 
resupended in 1mL of PBS and centrifuged again for 10 min at 4,500 rpm, resuspended in 0.5 mL 
of PBS, and stored at -20 °C for further analysis. All Pap smears were reviewed by the same 
pathologist.
DNA extraction andHPV-PCR assay
DNA extraction from the cervical cells was performed according to the Boom 
method as previously described.7 Two hundred microliters of material was isolated and 
resuspended in a final volume of 100 (xL; 10 (J.L was used for each ofthe various PCR analyses.
All samples were prescreened with the 6-globin primers PCO3/PCO5 to assess 
sample integrity.8
H P V  SPF10 Line Blot assay
(i) PCR amplification o f  H P V  DNA
Broad-spectrum HPV DNA amplification was performed using a short PCR 
fragment assay (HPV SPF10 Line Blot assay; Labo Bio-medical products B.V. Rijswijk, The 
Netherlands). This assay amplifies a 65-bp fragment of the L1 open reading frame, and allows 
detection of at least 43 different HPV types. SPF10 PCR was performed as previously 
described.9,10
Appropriate negative and positive controls were used to monitor the performance of 
the PCR method in each experiment. To avoid contamination by PCR products, sample 
preparation and the amplification reaction were all performed in separate rooms.
The presence of HPV DNA was determined by hybridization of SPF10 amplimers to a 
mixture of general HPV probes recognizing a broad range of high-risk, low-risk and possible 
high-risk HPV genotypes in a microtiter plate format, as described previously.9,10 All HPV DNA 
positive samples (by SPF10 DEIA) were genotyped using the HPV SPF10 Line Blot genotyping 
assays.
(ii) H PV genotyping by reverse hybridization using the H P V  SPFW Line Blot genotyping system
The 28 oligonucleotide probes which recognize 25 different types were tailed with 
poly (dT) and immobilized as parallel lines to membrane strips (Labo Bio-medical products B.V. 
Rijswijk, The Netherlands). The HPV genotyping assay was performed as described previously.9 
The LiPA strips were manually interpreted using the provided reference guide.
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The samples that tested positive using the DNA Enzyme Immuno Assay but showed no 
results on the LiPA strip were considered to be an HPV X-type i.e. genotypes not present on the 
LiPA strip.
Data Analysis
Statistical analyses were perfomed using the programs EpiInfo 6.02 (Centers for 
Disease Control and Prevention, Atlanta, GA), MS Excell (Microsoft Corp, Redmond, WA) and 
LogXact version 4 (Cytel, Cambridge MA).
Univariate statistics was calculated for all variables. Any P  value less than 0.05 was 
considered significant. Odds ratios (ORs) and 95% confidence intervals (CIs) were obtained 
from multiple logistic regression models to evaluate the association between HPV infections and 
risk factors. Multivariate logistic regression was used to control for potentially confounding 
factors. We adjusted for age using 4 groups contrasted as dummy variables (= 29, 30-39, 40-49, = 
50 years) and for HPV infection status (only low risk types and any high risk types).
We investigated the potential association with education, socioeconomic status, 
exposure to wood smoke, history of pregnancy, parity, age at first intercourse, lifetime number of 
sexual partners, number of previous screens, time since last Pap smear, history of sexually 
transmitted diseases and occurrence of other genital infections that could influence the 
development of SIL.
Results
Among the 289 women analyzed 139 had LSIL, 60 had HSIL, and 90 had CC. HPV 
DNA was detected in 113 women (81%) with LSIL, 58 women (97%) with HSIL, and 84 (93%) 
with CC. Single infections were detected in 67%, 57%, and 75% of LSIL, HSIL, and CC group 
respectively. Twenty-five HPV types were found; 8 samples had HPV types that could not be
Genotypes
Figure 1. Prevalence of individual HPV types among Honduran women according to condition
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identified and were classified as HPV X, 3 with HSIL and 2 with CC.
Among the cervical cancers 92% of cases were squamous, of which 60% were positive 
for HPV 16, 13% for HPV 45, 7% for HPV 18, 7% for HPV 31, 6% for HPV 39 and 5% for HPV 
51. The remaining 8% of cervical cancers were glandular of which 50% were positive for HPV 
18, 16% for HPV 16, 16% for HPV 45 and 16% for HPV 31.
HPV 16 was the most common type identified (Figure 1). Among each group HPV 16 
was found in 41% (46/112) of the IC cases, 35% (34/98) of the HSL cases, and in 24% (42/178) of 
the LSIL cases. HPV 18 was detected in 5% (9/178) of LSIL, in 4% (4/98) of HSIL cases, and 9% 
(10/112) of CC cases.
Ninety-three percent (236/255) of the HPV positive women were infected with hrHPV 
types and only 7% (19/255) were infected with lrHPV types. Women who were infected with both 
hr/lr types were grouped as HR types in the analysis. HrHPV age-specific prevalence was highest 
among women aged 50 or older (48/49, 98%), and slightly lower among women younger than 29 
years (45/50, 90%). Eighty-four percent of the HSIL and IC patients were older than 50 years 
(Table 1). We detected 5 LSIL positive for HPV 6 (3.6%) and 7 LSIL positive for HPV 11 (5%).
Table 1. HPV prevalence in Honduran women according to age, type of HPV infection and 
type of lesion
Age group, y
<29 30 - 3 9  40  -4 9  = 50
n % n % n % n %
HPV TYPES
Low Risk 5 10% 5 6 % 7 9% 1 2%
High Risk 45 90% 72 94% 71 91% 48 98%
Total 50 77 78 49
MULTIPLICITY OF INFECTION
Single 34 67% 52 68% 53 68% 34 69%
Multiple 17 33% 25 32% 25 3 2% 15 31%
Total 51 77 78 49
TYPE OF LESION
LSIL 42 82% 30 3 9 % 33 42% 8 16%
HSILor CC 9 18% 47 61% 45 58% 41 84%
Total 51 77 78 49
The number of pregnancies varied from 1 to 15, among which 65% (181/281) had four 
or more pregnancies. A linear dose-response relationship between HPV infection and number of 
pregnancies was observed, when considering all HPV types and all age groups combined.
The number of lifetime sexual partners varied from one to more than six, from which 
89% (254/287) had less than three lifetime sexual partners. A direct association between lifetime 
sexual partners and progression of the disease was detected, considering that 59% (111) of the 
189 women with more than one sexual partners were within the HSIL or CC group and that the 
risk of HPV infection was reduced for women with one lifetime sexual partner who were 44 years 
or older (0R=0.7,95%CI=0.5-1.0).
Eighty percent of the women had undergone one cytologic screening 11 months before 
the interview; 49 (36% of LSIL), and 40 (29% of HSIL or CC) women reported 4 or more
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occasions when they were screened. Five percent had never been screened before they were 
diagnosed. Women who had 4 or more previous screens had a reduced risk of progression to HSIL 
or CC. When analyzing the number of previous screens an 0R=2.31 for women who had 
undergone cytologic screening longer than 11 month before the interview was observed.
The association with exposure to wood smoke was statistically significant both in 
women with single HPV infection (OR = 4.6, 95% CI = 3.0-7.1) and in women with multiple 
HPV infection, (OR=5.7, 95% CI = 3.3-9.9). Other factors that remained slightly significant, 
such as early sex debut and socioeconomic status (SES), are shown in Table 2. When doing 
multivariate logistic regression analysis a statistically significant association for progression of 
the disease was ascertained for women who had a low SES (OR=1.8, 95% CI=1.2-2.5).
Table 2. Risk factors for HPV DNA detection among Honduran women with LSIL, 
HSIL and invasive CC
LSIL n (%) HSIL/Invasive CC, n (%) OR
Age (years)
= 29 42 (37)
30 -  39 30 (27)
40 -  49 33 (29)
= 50 8 (7)
Women’s education (years)
None 10 ( 9)
1 -  3 20 (19)
4 -  6 53 (49)
= 7 25 (23)
9 (6) 
47 (33) 
45 (32)
41 (29)
35 (25)
42 (30) 
45 (32) 
19 (13)
1.00 
7.31 
6.56 
23.92 
X2= 17.713 / p<0.00
1.00
0.60
0.24
2 0.22 
X = 17.193 / p<0.00003
Socioeconomic status
Medium
Low
60 (55) 
50 (45)
46 ( 32) 
96 (68)
1.74 (1.01 < OR < 3.01) 
X2= 4.48 / P<0.034
Exposure to Wood Smoke
No
Yes
Parity 
0 -  3 
4 -  6 
= 7
Parity before 23 years old
0 - 1
2
=3
Age at first intercourse, y 
= 18 
= 17
36 (26) 
100 (74)
71 (53) 
43 (32) 
19 (14)
50 (37)
51 (38) 
33 (25)
60 (44) 
76 (56)
10
136 (79)3)
29 (20) 
65 (44) 
54 (36)
35 (24) 
48 (33 ) 
63 (43)
57 (39) 
91 (61)
4.90 (2.21 < OR < 11.10) 
X2= 19.86 / P<0.0000083
1.00
3.70
6.96
X2= 36. 082 / P<0.00
1.00
1 .34 
2.73
X2= 10.962 / P<0.00093
1.26 (0.76< 0R< 2.08) 
X2= 0.92 / P<0.338
Lifetime No. of sexual partners
1 60 (43) 
= 1 78 (57)
No. previous screens
= 4 49 (36)
2 -  3 69 (51) 
0 -  1 17 (13)
Time since last pap smear 
(months)
0 -11 111 (87)
> 11 17 (13)
38 (26) 
111 (74)
40 (29) 
71 (51) 
29 (21)
96 (74) 
34 (26)
2.25 (1.32 < 0R < 3.82) 
X2= 10.29 / P<0.001
0.48 
0 .60
1 .00
X2= 3.606 / P<0.055
2.31 (1.16 < OR < 4.63) 
X2= 6.74 / P<0.009
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Discussion
Our study shows strong associations between invasive CC and HPV-16 and HPV-18 and 
to a lesser extent, with HPV-31, HPV- 45 and less common with HPV-51. Although we did not 
find HPV 58 in CC, it was highly detected in HSIL.
Despite the relative small sample size, the association of invasive CC with specific HPV 
genotypes in Honduras is consistent with previous studies from Honduras and with those 
observed in other countries from Latin America.10-15 By using a novel, more sensitive system for 
HPV genotyping, we were able to detect 25 different HPV types related to SIL and CC compare to 
only fourteen detected in the previous study done in Honduras.10,11
In this study, among HSIL and invasive CC cases, HPV- 16 infection alone was the most 
prevalent single HPV infection (35% and 50% respectively). More than half of the samples 
analyzed had infection with either HPV -16 or HPV-18 alone or both. The high rate of CC in 
Honduras in comparison with other countries could be attributable to the high prevalence of HPV 
infection and the general lack of available and effective cytologic screening.
The significantly increased risk of CC associated with never having had a Pap smear, 
high parity, low SES, early sex debut, and a greater number of sexual partners are consistent with 
previous studies.10,16-20 In the present study, there was an association between HPV infection and 
the use of wood for cooking, as was also found previously in a case-control study performed in 
Honduran women.21 All this evidence coupled with the disseminated use of wood for cooking all 
over Latin America is important enough to warrant further investigation. Younger age at first 
intercourse is related not only to increased rates of cervical abnormalities in young women but 
also to a higher risk of progression to CC.
Previous studies performed in other populations have suggested that although the 
benefit of the vaccine is clearly highest when given to an HPV- naive population, there is still a 
significant reduction in HPV-related precancerous lesions when given to the general population 
regardless of HPV status.22
Considering the proportion of abnormal lesions found to be associated with HPV -16 
and/or 18 infection in this population, it could be estimated that the implementation of the 
prophylactic vaccines against the HPV-16 and HPV-18 will have the potential of preventing at 
least a quarter of LSIL, one third of HSIL, and about half of CC cases in Honduras, assuming that, 
in the multiple infections cases, HPV-16 or HPV-18 was the causative agents of the lesion.
We have to consider that Honduras has an efficient vaccine program, with coverage 
greater than 80% of the children younger than 5 years. Nevertheless, for the introduction of an 
HPV vaccine, other factors should be considered, but the previously mentioned fact is an 
indication that vaccination programs are feasible in our country.
Although a small percentage of LSIL was caused by HPV-6 and HPV-11, it would be 
interesting to study the effect of a vaccine including these types to prevent genital warts because 
this association was not considered in our study.
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The advent of new technologies for HPV DNA testing and the introduction of the HPV 
vaccine have increased optimism about the potential for effective disease control in low-resource 
settings. In low -resource countries where CC screening programmes and treatments are scarce or 
absent, HPV vaccine raises considerable expectations. That HPV types vary between regions in 
the world and the strains targeted by the currently marketed vaccines may not prevail in low- 
resource countries, more extensive epidemiologic study of HPV typing are needed to contribute 
to determining the efficacy of the vaccine in this population.
The efficacy and efficiency of the two HPV vaccines available today have been proven 
to reach 100%, meaning that close to all cervical abnormalities and CCs caused by either HPV -16 
or HPV-18 (and partly other HPV genotypes by cross-immunity) can be prevented. In a 
population such as that of Honduras with a high CC burden, the introduction of vaccine 
campaigns will thus lead to significant reductions in the incidence of CC. It is therefore, a 
dramatic lowdown that because of the high costs of vaccination, this benefit will not be available 
for low-income countries despite the need for this vaccine.
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Abstract
Objective. To determine the prevalence of C. trachomatis and Human papillomavirus (HPV) 
in young Honduran women attending the Universidad Nacional Autónoma de Honduras.
Methods. 100 cytological normal female university students in Honduras were assayed for the 
presence of C. trachomatis by direct antigen immunofluorescence and HPV DNA by a short- 
fragment PCR (SPF) hybridization line probe assay (LiPA) which detects and genotypes 25 
different genital HPV types simultaneously.
Results. Overall 28% of the students were HPV positive and 6% were found to be positive for C. 
trachomatis.
Conclusion. These results show that genital HPV and C. trachomatis infections are very 
common among sexually active young women in Honduras. It is vital to promote extensive 
public awareness campaigns among sexually active women concerning preventive measures of 
these diseases.
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Introduction
Carcinoma of the cervix is one of the most common types of cancer in the developing 
world and the leading cause of death from cancer among women. Worldwide death rates of 
500,000 per year have been reported, of which 80% occurs in developing countries. In Central 
and South America, the incidence rate is approximately five times as high as in Western Europe. 
Honduras is no exception, with ahospital cervical cancer registry o f833 cases in 2001
Infections with human papillomavirus (HPV) are prevalent in the general population, 
ranging from 20% to 46% in young women in different countries. Epidemiologic studies indicate 
that 50% of women contract a genital HPV infection within two years of becoming sexually 
active.2'3 The lifetime risk of a genital HPV infection is estimated to be 80%, but only a small 
number of these women will develop cervical cancer.4
Chlamydia trachomatis is the most common sexually transmitted bacterial infection in 
the world and sexually active young persons are at highest risk.5,6 Little is known about the 
prevalence of these infectious agents in Honduras. Therefore the absence of this information 
limits the ability of public health officials to design effective prevention strategies. To address 
this deficit, the present study was conducted to determine the prevalence of C. trachomatis and 
HPV infections in young Honduran women attending the Universidad Nacional Autónoma de 
Honduras, in Tegucigalpa, the capital of Honduras.
4
Materials and methods
Study population
We conducted a cross sectional study to investigate the prevalence of HPV and C. 
trachomatis in 100 female students between 18 and 35 years of age from the Health Program at 
the Universidad Nacional Autonoma de Honduras. Subjects were selected consecutively from 
this pool on a totally volunteer first-come, first-serve basis. After providing written informed 
consent, all the women in the study received a physical examination, including a pelvic 
examination by a gynecologist. A standard validated questionnaire was used to interview the 
subjects regarding their medical history, use of contraceptives and sexual behavior, smoking 
habits and other HPV- and Chlamydia-associated risk factors.
Sample collection
Two smears were made, one for cytologic examination and the other for direct detection 
of C. trachomatis by immunofluorescence. Two additional scrapes were collected in transport 
medium to assay for HPV by extraction of DNA and a polymerase chain reaction (PCR) and for 
C. trachomatis by an enzyme linked immunoassay. The samples were immediately transported 
on ice to the molecular biology laboratory at the Universidad Nacional Autonoma de Honduras. 
The study was reviewed and approved by the Ethical Committee of The School of Medicine of 
the Universidad Nacional Autonoma de Honduras.
Detection o f C. trachomatis
A direct immunofluorescence antigen detection assay (Bio-Rad Laboratories, Hercules, 
CA) was conducted on the endocervical specimens to detect the 15 serovars of C. trachomatis. 
Endocervical specimens were also tested by a solid phase enzyme immunoassay 
(chlamydiazyme Abbott Laboratories, Chicago, IL) for chlamydial antigen. For the analysis of 
HPV, cervical scrapes were taken from the transformation zone with an Ayre wooden spatula and 
the cells eluted in 5 mL of phosphate-buffered saline containing 0.05% thimerosal and processed 
according to the method of Boom and others as previously described.7
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PCR amplification o f HPV DNA
All samples were prescreened with the p-globin primers PC03/PC058 to assess sample 
integrity. Broad-spectrum HPV DNA amplification was performed using a short fragment PCR, 
which can detect at least 43 different HPV types.9 A single-reaction reverse hybridization line 
probe assay (LiPA) capable of simultaneous detection and identification of 25 different HPV 
types was used to test the HPV-positive samples.10
DataAnalysis
Data were analyzed using Epilnfo statistical program (Centers for Disease Control and 
Prevention, Atlanta, GA). Statistical significance was determined by Fisher's exact test. Any p  
value 0.05 was considered significant. To increase the positive predictive value o f C. 
trachomatis results, only women with positive results in both the EIA and the direct 
immunofluorescence test were considered.
Results
We enrolled 110 female university students attending the Health Program at the 
Universidad Nacional Autonoma de Honduras for various reasons (mainly for advice on 
contraceptive use, reproductive tract problems, or routine physical examinations). One hundred 
agreed to participate in the study. The participants ranged in age from 18 to 35 years (mean = 24 
years). The average number of lifetime sexual partners was two, and the average age o f first 
intercourse was 21 years. All women had normal results on cytologic smears.
Twenty-eight (28%) of the students were positive for HPV. The results are summarized 
in Figure 1. Six of the 28 women positive for HPV were infected with a single HPV type. Overall, 
19 different genotypes were detected, and HPV-11 and HPV -51 were the most common types. 
The majority (89%) of the HPV -positive university students were positive for HPV-16 and 
related types (31,33,35,52 and 58), and 46% were positive for HPV-18 and related types (45 and 
59).
6 11 16 18 31 33 34 35 40 44 45 51 52 53 58 66 70 74 X
HPV TYPE
Figure 1. Prevalence of individual HPV types in cervical scrapes of Honduran university 
students detected by SPF-PCR and genotype by LiPA
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In one woman, only the conjugate control line of the HPV-LiPA strip was colored, and 
no reaction with the HPV type-specific probes was observed. This suggests the presence of an 
HPV type that was not included in the detection strip (HPV X). We observed a high prevalence of 
cervical scrapes containing multiple HPV types. Of the 100 women tested, 22% contained more 
than one HPV type: six women had two different HPV types, eight had three types, four had four 
types and four had five or more types.
Of the 100 women tested, 6% were infected with C. trachomatis, as indicated by 
positive enzyme immunoassay and immunofluorescence test results. None of the positive 
women had a history of C. trachomatis infection. At the time the sample was taken, only 2% had 
leukorrhea. Four women were positive for both HPV and C. trachomatis. A statistically 
significant association was observed between detection of HPV DNA in cervical scrapes and 
positivity for C. trachomatis antigen positive (OR= 5.83,95% CI = 0.84 -49.51, P=0.05).
Table 1. R isk factors associated w ith hum an papillom avirus (HPV) and C hlam ydia  
tracho m a tis  - positive infections in Honduran university  students
HPV DNA and 
C. trachomatis C. trachomatis_  . ,. HPV DNA antigen positive, antigen positive,Characteristic positive, no. (%) no. (%) no. (%)
Age, years
s? 2 5 16(57) 3 (50) 2(50)
26-30 7 (25) 2 (33) 2 (50)
>31  5(18) 1(17)
Marital status
Single 16 (58) 3 (50) 1 (25)
Married 12 (42) 3 (50) 3 (75)
Age at first 
intercourse, years
< 25 25 (89) 5 (83) 3 (75)
> 25 3 (11) 1 (17) 1 (25)
We observed that single female students (58%) were more likely to be infected with 
HPV than married women (42%). Conversely, for women infected with both HPV and C. 
trachomatis, married women were more likely to be infected (75%). Those with a positive result 
for HPV DNA (57%) or C. trachomatis (50%) were significantly younger (<25 years of age) and 
had sexual intercourse for the first time at a younger age (< 25 years of age) (89% and 83%, 
respectively) than those with a negative result (Table 1). Other variables such as menarche, 
contraceptive use, pregnancies, abortions, smoking, and a family history of cancer did not show 
statistically significant differences and were not tabulated.
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Discussion
This study reports prevalence of C. trachomatis and HPV in female Honduran 
university students. Chlamydia trachomatis was detected in 6% of the students and HPV in 28%. 
O f the 28 women positive for HPV, 22 contained more than one HPV type. The significance of 
multiple infections is not clear. Previous studies found that infection with multiple HPV 
genotypes increases the likelihood of persistent HPV infection in healthy young women,11 and 
might also contribute to the development or progression of cervical dysplasia,12 but more studies 
are needed to clarify the importance of multiple HPV infections.
In agreement with the results of previous studies, we found that the prevalence of HPV 
in women less than 25 years of age was significantly higher than in older women.13 Positivity for 
C. trachomatis was also higher in students less than 25 years than in older women. When the 
epidemiologic data of the university students were analyzed, we observed that the percentage of 
women infected with C. trachomatis decreases with age. Since this is a sexually transmitted 
infection, it is possible that women more than 25 years old are involved in more stable 
relationships and less exposed to this infection.
None of the women had a history of C. trachomatis infection. At the time when the 
sample was taken, only 2% had leukorrhea, a finding that must be considered when documenting 
the presence of asymptomatic infections with C. trachomatis. This is relevant since this silent 
infection can lead to severe complications and also represents a potential source of infection for 
their partners.
Infection with HPV is common, especially in young, sexually active women worldwide. 
However, not every women infected with HPV develops cervical cancer. Clearly, additional 
virologie, environmental, immunologic or genetic factors must be implicated in the pathogenesis 
of cervical cancer.
Ferrera and others14 found that 39% of Honduran women with negative cytologic test 
results for cervical cancer were positive for HPV. In addition to the strong association between 
HPV and cervical cancer, dose-response relationships were observed for education level, age at 
the time of sexual intercourse for the first time, and exposure to wood smoke, levels of antibodies 
to C. trachomatis were higher in cases of cervical intraepithelial neoplasia grade III and invasive 
cancer than in the corresponding controls, although this difference was not statistically 
significant.
Four percent of the university students were positive both for C. trachomatis and HPV. 
Although this finding was statistically significant, the population was too small to make a clear- 
cut association between these two pathogens. Many studies have consistently indicated a 
potential etiologic role for infection with C. trachomatis as a cofactor of HPV in the development 
of cervical cancer.15"18 If C. trachomatis modulates the immune response of the host, it should be 
considered an important cofactor in HPV-induced carcinogenesis.
In conclusion, we found a prevalence of 6% for C. trachomatis and 28% for HPV in 
Honduran female university students. The incidence of sexually transmitted infections continues 
to be a major health problem in Honduras. Thus, identifying young persons infected with C. 
trachomatis and HPV is of paramount importance in preventing cervical diseases, especially 
cervical cancer. This will also help in determining the prevalence of sexually transmitted 
infections and improving prevention strategies.
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Abstract
Objective. To evaluate ROCHE Linear Array Assay performance characteristics in detection of 
HPV type specific prevalence among young university students from the Honduras National 
University (UNAH) and their association with possible risk factors, in order to provide baseline 
information for assessing the impact of vaccination programmes.
Method. Four hundred university students aged 18 to 35 years were typed using the Roche HPV 
Genotyping Assay, to differentiate 37 genotypes. Risk factors were associated with the crude 
odds ratios and X2 test.
Results. HPV DNA was detected in 45% of the samples, whereof 73% were infected with high 
risk types and 46% presented multiple infections. Thirty six genotypes were encountered, being 
HPV types 16, 51, 84, 66 and 39 the most common. There was a marked decline in prevalence of 
multiple and high risk infections with age. The factors independently associated with risk of 
being infected, were related to sexual behavior and smoking habits.
Conclusion . Our results demonstrated that genital HPV infection is common among sexually 
active university women. Furthermore, the Roche LA Assay was proved a valuable tool for HPV 
genotyping, which is a valuable tool for monitoring the effectiveness of an HPV vaccine in the 
population.
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Introduction
Human papillomavirus (HPV) is one of the most common sexually transmitted viruses 
among young women; most, if not all, sexually active women get infected by one or more HPV 
types during their lifetime. Although most infections are transient, the potential health 
implications are obvious, since HPV types 16 and 18 cause 70% of cervical cancers, and other 
types (for example 31, 33, 35, 39, 45, 52, 56 and 58) have an important role in cervical 
carcinogenesis as well. 1
Although the process of development of cervical cancer may take decades, infection 
with high risk (hr) types and the presence of risk factors that promotes persistence of the 
infection, precede the development of precancerous lesions that in time may evolve to invasive 
cancer. The risk factors that promote HPV infection and its persistence are either biological, as 
coinfection with other STDs or behavioral, as sexual habits and substance use .2-4
Given the effect of this infection on public health, prophylactic vaccines against HPV 16 
and 18 have been developed. However, to assure the efficacy of the vaccines, it is essential to 
create baseline information of the acquisition of HPV by young women and the epidemiology of 
type specific HPV due to behavior. With the introduction of prophylactic vaccines, it is also 
important to monitor HPV infections in order to oversee changes in HPV epidemiology in time .5 -7
Although screening for cervical cancer precursors by cytology has been very 
successful, it is generally inefficient and unworkable in many parts of the world where the 
appropriate infrastructure is not achievable.8
Accordingly, many ongoing international research projects assess the feasibility of 
introducing hr HPV tests as a risk marker for cervical cancer. For these screening purposes, 
several tests have been developed in order to detect hr HPV infections. Among these are the signal 
amplification methods Hybrid Capture II (hcll) and Cervista. 9-10
Recently, the ROCHE Linear Array (LA) HPV genotyping test (ROCHE Molecular 
Systems Inc. Branchburg, NJ) has launched an HPV genotyping assay able to genotype 37 HPV 
types, concurrently assessing human P-globin.
In past HPV epidemiological studies performed in Honduras,11,12 we have used the 
SPF10-INNO LiPA assay, a highly reliable typing method amplifying up to 43 different 
genotypes and providing type-specific genotype information for 25 different HPV genotypes 
simultaneously. In this context, the SPF10-INNO LiPA and the Linear Array HPV genotyping 
assays are highly congruent for the genotypes detectable in both assays. Furthermore the 
manageability of both assays is highly comparable.9
To widen knowledge about the molecular epidemiology of HPV in Honduras, we 
performed a descriptive and cross sectional study among young university students of the 
Universidad Nacional Autonoma de Honduras (UNAH) from Tegucigalpa, to determine HPV 
prevalence, HPV genotypes distribution using the Linear Array assay from ROCHE and the 
association with risk factors that promote infection with HPV. The information emanating from
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this research will broaden baseline information about the acquisition of HPV infections by young 
women and the epidemiology of specific HPV types in the context of the implementation of 
vaccine campaigns.
M aterials and methods
Study population and study design
This prospective epidemiologic study was performed among 400 female students aged 
18 to 35 years. Women were recruited at the Health Program of the University National 
Autonoma de Honduras (UNAH), where the majority of women came for a routine gynecology 
consult or family planning advice. According to the clinical evaluation most of the patients had no 
health problems while a minority presented common gynecological infections, such as mycosis 
or bacterial vaginosis.
The subjects became part of this study on a voluntary basis, signed a written consent and 
filled out a standard validated questionnaire. The questionnaire was used as an interview to obtain 
knowledge regarding the students' medical history, as well as habits and factors considered to 
increase the risk of cervical cancer, as sexual behavior, smoking habits, and parity. The study was 
reviewed and approved by the appropriate Ethical Committee.
Specimen Collection and Processing
All the women participating in this study were submitted to a general pelvic 
examination by a gynecologist to determine their general clinical condition and to collect a 
cervical smear.
Two samples were collected from each patient, one which was immediately fixed for 
cytological examination and a second sample, taken for further HPV analysis, was placed in 5 mL 
sterile phosphate-buffered saline (PBS), 0.005% thimerosal and transported to the laboratory on 
daily basis, within two hours from sampling. Upon arrival to the laboratory, cells were washed 
with PBS, centrifuge (15 min at 5000 rpm), the supernatant was removed and the sample pellet 
was resuspended in 1mL PBS. This process was repeated, to finally resuspend the cells in 0.5 mL 
PBS, and stored at -20 °C, for further use.
DNA Isolation
Purified DNA was attained from a 250 ^L aliquot from the sample suspension. This 
aliquot was treated with the DNA purification procedures, reagents and material provided by the 
QIAamp MiniElute Media Kit for liquid media using vacuum systems from Qiagen (Valencia, 
CA). DNA was finally eluted from the columns using 100 (J.L of Promega Nuclease free water.
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PCR Amplification o f  HPV DNA
HPV genotyping was performed by the LINEAR ARRAY HPV Genotyping Test 
(Roche Molecular Systems, Branchburg, NJ) which uses biotinylated primers to define a 
sequence of nucleotides within the 450-bp fragment on the polymorphic L1 region of the HPV 
genome. The master mix of this test includes a pool of 37 HPV genomes, including 13 hr 
genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and the human P-globine gene to 
provide control for cell adequacy, extraction and amplification.
The PCR Amplification was performed with a final volume of 50 ^L, containing 10 
of the isolated DNA sample and 40 (J.L of the PCR master mix, that includes Tris buffer, potassium 
chloride, MgCl2 < 0.1% AmpErase (Uracil-N-glycosylate) enzyme, < 0.001% dNTP (dATP, 
dCTP, dUTP, dGTP, dTTP), <0.001% each of the forward and reverse primers, 0.06% Sodium 
azide and 0.02% of AmpliTaq Gold DNA Polymerase. The mixture was incubated for two 
minutes at 950C, followed by 40 cycles of 30s at 950C, 1 min at 550C, 1 min at 720C and a final 
extension at 720C. Each experiment was performed with a separate positive and negative PCR 
control. The AmpErase enzyme is included to prevent PCR carryover contamination.
Hybridization and Detection o f  HPV
Following amplification, the HPV and human 6-globine amplicons were denatured by 
immediately adding 100 (J.L of denaturation solution to each PCR tube. Aliquots of the denatured 
amplicons were transferred to a tray containing hybridization buffer and a single Linear Array 
HPV Genotyping strip (Roche Molecular Systems, Branchburg, NJ). There, the biotinylated 
amplicons hybridized with the oligonucleotides, only if the amplicons contained the 
complementary probe. This phase was completed by washing the strip with a stringent solution, 
to remove unbound material.
Following the hybridization, Streptavidin-Horseradish conjugate was added to the strip, 
to ensure the binding of the biotin-labeled amplicons to the oligonucleotide probes on the strip. A 
subsequent addition of substrate solution containing hydrogen peroxide and 3, 3', 5, 5'- 
tetramethylbenzidine (TMB) was performed, to form a blue colored complex, which precipitates 
at the probe position where hybridization occurred. The LA HPV genotyping strips were 
manually interpreted using the HPV reference guide.
Data Analysis
Results were analyzed with the aid of the software EpiInfo 6.02 (CDC) statistical 
program. To assess the association between the characteristics of the subjects and the infection, 
the crude odds ratio with a 95% exact confidence interval was used. In addition, comparison of 
the frequencies of HPV infection between age groups was performed by the X2 test. A level ofp= 
0.05 was considered significant.
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A total of 400 female students were initially recruited, however seven subjects did not 
fill in the questionnaire properly and were consequently withdrawn from the study. HPV DNA 
was detected in 176 (45%) of the 393 women. Hr HPV genotypes were more prevalent, and were 
detected in 129 (73%) of the 176 HPV positive samples, while in 47/176 (27%) samples, lr HPV 
genotypes were detected. Samples infected with both hr HPV and lr HPV types were included in 
the high risk group as shown in figure 1.
Age specific prevalence of HPV DNA is shown in table 1 and figure 1, where a strong 
inverse relation between age and hr HPV incidence is observed, while the proportion of lr HPV 
infections remained constant regarding the age of the women. A considerable decrease of hr HPV 
infection was observed after the age 25.
Results
■ <: 21 
2 2 - 2 5
■ 2 6 - 2 9
■ & 30
Though single HPV type infections were found in 54% (95/176) of the samples, the 
positivity of multiple types infections was high and 46% (N=81) of the positive HPV DNA 
samples was positive for more than one type. Frequently, multiple infections included at least one 
hr HPV type (88%, N = 71). Both multiple and single HPV infections showed an inverse relation 
with age, though this was more noticeable in women older than 25 years with multiple HPV 
infection.
There were 36 genotypes detected from the 37 that the Linear Array probe detects. As 
seen in figure 2, among the hr HPV group, the most prevalent were the HPV types 16 (18%, N = 
31), 51 (14%, N = 24), 66 (11%, N = 19) and 39 (11%, N = 19). While the types 18, 31, 33, 45 were 
detected in 3% (N = 6), 6% (N = 10), 1% (N = 2) and 3% (N = 5), respectively. Meanwhile, the 
most prevalent types from the lr HPV group were the types 84 (11%, N = 20), 61 (9%, N = 16) and 
62 (9%, N = 16).
35 % 
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Figure 1. Prevalence of lr/hr types and multiple and single infection by age.
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Figure 2. Prevalence of HPV genotypes among Honduran female students
The presence of HPV DNA was associated to several risk factors by a multivariate 
analysis. The factors independently associated with a risk of being HPV positive, excluding age 
and Pap smear result, were related to sexual behavior and smoking habits.
Among the most prevailing predictors of HPV DNA prevalence and hr-risk types 
infection, were the number of lifetime sexual partners (X2 = 12.447 / P< 0.00042), smoking habits 
(X2 = 11.12 / P< 0.000852), number of sexual partners before age 21 (X2 = 5.36 / P< 0.020558) and 
age at first intercourse (X2 = 5.26 / P< 0.021854).
In addition, there were other factors related to the screening and birth control habits 
significantly associated with HPV DNA prevalence and hr types infection; within which are the 
lifetime number ofpap smears (X2 = 4.89 / P< 0.02703), time since last pap smear (X2 = 1.586 / P< 
0.20784) and history ofbirth control (X2= 2.03 / P< 0.154152), as shown in table 1.
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Table 1. Risk factors for HPV DNA and high risk types detection and simple infections 
among Honduran female students
HPV Positive (N= 176) High risk HPV types (N=129) HPV single detection (N = 95)
% OR % OR % OR
Age (years)
< 21 48.8 3.17 35.0 3.41 26.3 2.56
22 -25 44.6 2.69 34.5 3.11 23.7 2.14
26 -29 37.2 1.98 23.3 1.85 20.9 1.05
< 30 23.1 1.00 15.4 1.00 15.4 1.00
X2= 4.008 / P< 0.04527 X2=3.660 / P< 0.05575 X2=5.090 / P< 0.02406
Life time sexual partners
1 39.2 1.00 28.3 1.00 20.7 4.90
2 -3 48.5 1.46 35.4 1.48 27.7 1.58
< 4 76.9 5.16 61.5 5.73 38.5 1.00
X2=12.447 / P< 0.00042 X2=12.452/ P< 0.00042 X2= 9.616/ P< 0.00193
Age at first intercourse
>18 42.3 1.00 40.0 1.00 35 1.00
< 17 58.3 7 <x 0 o, A << 2. 2 31.6 1.76 (0.92 AORA3.37) 22.2 2.18(1. 10A0RA4.33)
X2= 5.26 / P< 0.021854 X2=3. 34/ P< 0.0676231 X2=5.89 / P< 0.015236
No. of Sexual Partners
before age 21
< 1 41.8 1.00 41.5 1.00 21.9 1.00
2 -4 56.1 1.78 (1.06A0RA2.99) 30.6 1.8(1.02<0RA3. 16) 32.9 2.00(1.08A0RA3.67)
X2= 5.36 / P< 0.020558 X2=4.78 / P< 0.0287574 X2= 5.74 / P< 0.01659
Smoking habits
No 39.5 1.00 42.0 1.00 26.8 1.00
Yes 58 2.12(1 .33<0Ra 3.39) 29.2 2.07(1.24<0Ra 3.46) 23.1 1.67(0.94A0RA2.96)
X2=11.12 /P< 0.000852 X2=8.93 / P< 0.0028113 X2= 3.50 / P< 0.061449
Pap smear result
Negative 42.7 1.00 77.8 1.00 33.3 1.00
Positive 88.9 6).223RA2
O
A342(.70. 30.7 13.08(1.59 AORA286.91) 22.6 7.6(0.69<0R<192.84)
X2= 7.57 / P< 0.005921 X2=9.32 / P< 0.0022613 X2= 4.27 / P< 0.041087
No. of lifetime pap smears
0 47.9 2.01 34.6 1.78 27.1 2.92
1 49.6 2.15 35.3 1.8 8 26.9 2.62
<2 31.4 1.00 25.6 1.00 14 1.00
X2= 4.89 / P< 0.02703 X2= 2.93 / P< 0.0868 X2= 7.8 / P< 0.00523
Time since last pap smear
(months)
Never 47.9 1.36 34.6 1.42
<11 43.6 1.14 34.7 1.31
0 -11 40.4 1.00 27.9 1.00
X2= 1.586 / P< 0.20784 X2 1.496/ P< 0.22134
History of birth control
No 42.0 1.00 26.7 1.00
Yes 49.3 1.16 (0.73 AORA1.84) 22.6 1.35(0. 80<ORa2 .28)
X2= 2.03 / Pa 0.1 54152 X2= 1.42 / P< 0.233579
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Discussion
The prevalence of HPV in Honduran university students was 45%. Seventy-three 
percent of the infected women were infected with hr HPV genotypes and 46% presented multiple 
infections. The prevalence of HPV was similar to other studies in Honduran college women as 
previously demonstrated.11 Also, it has been proven that age is an intrinsic risk factor, with higher 
prevalence rates among younger women (less than 21 years). For instance, in the United States 
64% of teenagers studied were found infected and 77% of them were infected with hr HPV 
genotypes.
As in concordance to previous studies, in our study group, age was a determinant factor for 
prevalence; it was higher among younger women (less than 21 years) and considerably reduced 
after age 25.13-18 These results were even more noticeable within women with multiple infections 
and hr genotypes. However, general positivity was reduced in women with lr genotypes and in 
women with single infection.
Our results are in agreement with previous studies where HPV type 16 was the most 
prominent genotype, found in 18% ofthe cases, distributed among all the age ranges.15,19-21
HPV 51 was also relatively often detected, found in 14% of the samples, but mostly 
within women younger than 25 years. Even though in Honduran women with normal cytology, 
HPV 51 has been often detected,11,12,22 we did not find it to be associated to the development of 
cervical cancer, this could indicate that HPV 51 does not cause persistent infections that can lead 
to HSIL and cervical cancer.
HPV 66 and HPV 39 were also highly detected, present in 11% HPV positive women. 
The high incidence rates of HPV 16 and 51 that were seen in our group have also been observed in 
a cohort of university students in New York23 and in young women attending gynecology clinics 
for routine screening in Arizona.24
HPV prevalence was linked to life-style risk factors, in which sexual behavior, smoking, 
and reduced or lacks of screening were the most common factors that promoted HPV infection. 
As established in several international studies, sexual behavior and number of sexual partners are 
the most important risk factors involved with HPV acquisition.25-27 This was confirmed in this 
study, in which the main determinant factor in contracting one or more HPV types was the 
number of life time sexual partner, followed by other sexual behavioral habits such as age of first 
intercourse and number of sexual partners before age 21.
Given the high proportion of smokers among this study group, (100/393) it was possible 
to determine the influence of smoking on the HPV prevalence; thus a strong risk for HPV 
infection was found in smokers. This association was not encountered in previous studies 
performed in Honduras in women of low socioeconomic status who do not have smoking 
habits.12,27
Other studies have found smoking as an independent risk factor for cervical cancer.28,29 
Inhalation of cigarette smoke has been linked to the secretion of tobacco specific substances in
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the cervical mucus,30-33 such as cotinine and nicotine. The presence of the tobacco-specific 
nitrosamine NNK, a known carcinogenic substance34 has been demonstrated in the cervical 
mucus of smokers.35
We also analyzed the association between screening frequency and HPV prevalence, 
women with fewer screens tend to have higher HPV incidence. This is consistent with previous 
international and national studies, providing further evidence that global cervical cancer control 
strategies should focus on improving the access to and quality of cytological screening services, 
while envisioning the use of HPV vaccines and HPV screening for the prevention and detection 
of specific hr HPV type infections.11,12, 36
In addition, there was a slight direct relation between the use of birth control and HPV 
prevalence, as demonstrated in other studies.37,38 Use of oral contraceptives for five or more years 
is a cofactor that increases up to fourfold the risk of cervical cancer among women who are 
carriers of HPV DNA.37 Because of the potential public health importance of confirming the 
interaction between the long term use of OCs and HPV infection in the development of cervical 
cancer, efforts are now being devoted to confirm the results in different populations.
HPV DNA testing and genotyping with the ROCHE LA assay, allows a high sensitivity 
to detect a broader spectrum of genotypes comparable to the SPFIO-INNO LiPA assay9 as they are 
both highly standardized, including reagents, amplification profiles, hybridization and detection 
conditions for optimal sensitivity and reproducibility. This similarity among both assays is a 
significant factor among young women that have multiple HPV infections. Even though, most of 
those types are not considered high risk types, their epidemiology might be changed by the 
introduction of the vaccine therefore it is important to continuously track changes in their 
prevalence and persistence.
Furthermore, the results obtained from this study broaden the baseline information11 
about the HPV types prevalent contracted by young women in their early sexual life, which are 
usually degraded or otherwise persist and in time produce cervical neoplastic lesions, and also 
provide more insight on the behavioral risk factors involved in their epidemiology. This 
information is fundamental for the development and continuous improvement of the HPV 
vaccines and the assurance ofworthy vaccination programs.
This study demonstrates the greater sensitivity of HPV DNA testing compared to 
cytology in detecting early dysplastic changes, which argues strongly that established cytology- 
based programmes should also be gradually moving towards a greater use of HPV DNA testing to 
improve their efficacy and safely lengthen the screening interval. HPV DNA testing should be the 
primary screening test in newly implemented programmes, except where resources are extremely 
limited and only programmes based on visual inspection are affordable. In such cases, use of a 
simple HPV DNA test followed by immediate 'screen and treat' algorithms based on visual 
inspection in those who are HPV-positive are needed to minimize the number of visits and make 
best use of limited resources. In this context, the Linear Array and the SPF10- INNO LiPA assays 
offer a reliable, sensitive and standardized approach for detecting HPV DNA in cervical
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Abstract
Objective. To investigate the relationship between HPV 16 viral load with respect to the grade of 
cervical disease in Honduran women.
Method. A real-time PCR allowing quantification of both HPV16 genome and 6-globin gene to 
normalize the measuring HPV16 load in cervical cells was used.
Results. The data in 87 women with cervical dysplasia or cervical cancer and in 23 women with a 
negative Pap smear were evaluated. The highest average of HPV 16 viral load was detected in 
women with High Squamous Intraepithelial Lesions (HSIL).
Conclusion. An increasing amount of HPV in higher cervical lesions was found, which could 
indicate a dose-response association between viral load and precancerous lesion grade.
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Introduction
Cervical cancer is a significant public health problem in Latin America and the 
Caribbean. By the year 2000, some 76,000 cervical cancer and almost 30,000 deaths were 
estimated for the whole region, which represent 16% and 13% of the world burden, respectively.1 
The vast majority of cervical cancer cases and deaths occur in developing countries where 
women have little or no access to effective disease prevention services. According to WHO 
statistics, Central America has one of the highest rates of death from cervical cancer in the world. 
Honduras is no exception with an age standardized rate of 30.6 per 100,000 inhabitants.2 Most 
women who die of cervical cancer -particularly in developing countries -are in the prime of their 
lives. They may be raising children, caring for their families, and contributing to the social or 
economic life of their towns. Their deaths are unnecessary because there is compelling evidence 
that cervical cancer is one of the most preventable and treatable forms of cancer, as long as it is 
detected early and managed effectively. Unfortunately, the majority of women in developing 
countries still do not have access to cervical cancer prevention programs. The consequence is that 
cervical cancer is not detected until it is too late to be cured.
The effect of high-risk types of HPV DNA infection on CIN development is highly 
influenced by viral number copies. In this context, measuring HPV load could improve the 
positive predictive value of HPV testing based on the assumption that higher load values are more 
strongly associated with severe disease.
Several studies have suggested that a high HPV-DNA viral load may be a candidate 
marker that could help identify women at greater risk of CIN progression.3-6 In fact, some studies 
have pointed out that high viral load in cytological normal epithelium could also be a risk factor 
for neoplastic progression.3,4
To increase our knowledge of HPV-induced carcinogenesis, we evaluated the 
relationship between HPV 16 copy numbers with respect to the grade of cervical disease to 
identify the existence of a HPV type-dependent viral load effect in Honduran women.
M aterials and methods
Study population
The samples analyzed are part of a study that was conducted in Tegucigalpa, Honduras 
from January 2003 to December 2005 in which 760 women were enrolled for the analysis of HPV. 
Cervical samples were obtained from 281 women aged 18 to 65 years with cervical dysplasia or 
cervical cancer attending San Felipe General Hospital, a referral centre for cancer patients. The 
histological diagnosis based on biopsy results determined the classification for each case in the 
study. At the same time, cervical samples were also taken from 479 women with normal cervix 
and a negative Pap smear 2 per women with cervical dysplasia or cervical cancer whenever 
possible, matched by age to a ±5-year interval and randomly selected from cervical screening 
clinics.
After formal written consent, a thorough physical examination was performed, and a 
structured epidemiological questionnaire was administered to each woman. The study was 
reviewed and approved by the correspondent Ethical Committee. A total of 118 samples from the 
women with cervical dysplasia were positive for HPV 16 (42%) and 44 of the women with 
normal cytology (9%).
From these 162 samples positive for HPV 16 there was not enough DNA to do the viral
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load from 52 samples, so 110 frozen cervical DNA specimens were available for this study, 23 
from the women with normal cytology, 25 samples from women with low squamous 
intraepithelial lesions (LSIL), and 62 from women with high squamous intraepithelial lesions 
(HSIL).
H P V  DNA detection 
Sample collection
For the analysis of HPV, cervical samples were taken from the transformation zone with 
an Ayre wooden spatula. Cells were eluted from the spatula in 5 mL of PBS (Phosphate Buffered 
Saline), pH 7.6 containing 0.05% thimerosal. Cells were vortexed, centrifuged for 10 min at 4500 
rpm, then resupended in 1mL of PBS and centrifuged again for 10 min at 4500 rpm, resuspended 
in 0.5 mL of PBS and stored at -20 °C for further analysis. DNA was extracted from thawed cells 
according to the standard Boom method as previously described.7 In brief, 200 (J.L ofmaterial was 
pipetted into a reaction vessel containing 30 ^L of celite and 1 mL of a guanidinium thiocyanate 
(GuSCN)-containing lysis buffer, released nucleic acid (NA) was bound to the celite, forming 
complexes that could be rapidly sedimented by centrifugation. These complexes were then 
washed twice with 1 mL of a GuSCN-containing washing buffer, twice with 1 mL of 70% 
ethanol, and once with 1 mL of acetone; the complexes were dried, and NA was subsequently 
eluted in a final volume of 100 ^L nuclease-free water; 10 ^L were used for each of the various 
PCR analyses. Every 5 samples, a negative extraction control was processed as well.
To avoid contamination by PCR products, sample preparation and the amplification 
reaction were all performed in separate rooms.
Qualitative P~globin detection
From the start, all samples were prescreened to assess DNA sample integrity with the P- 
globin primers PCO3 (5' ACA CAA CTG TGT TCA CTA GC 3') and PCO5 (5' GAA ACC CAA 
GAG TCT TCT CT 3')
H P V  SPFI0 Line Blot25 assay
(i)PCR amplification o f  H PV DNA
Broad-spectrum HPV DNA amplification was performed using a short PCR fragment 
assay (HPV SPF10 Line Blot 25, Labo Bio-medical products B.V. Rijswijk, The Netherlands). 
This assay amplifies a 65-bp fragment of the L1 open reading frame, and allows detection of at 
least 43 different HPV types.8,9
Appropriate negative and positive controls were used to monitor the performance of the 
PCR method in each experiment.
(ii)HPV detection byDEIA
The presence of HPV DNA was determined by hybridization of SPF10 amplimers to a 
mixture of general HPV probes recognizing a broad range of high-risk, low-risk and possible 
high-risk HPV genotypes in a microtiter plate format, as described previously.9,10 All HPV DNA 
positive samples were further genotyped.
(iii)HPV genotyping by reverse hybridization using the H P V  SPF10 Line Blot 25 genotyping 
system
The 28 oligonucleotide probes that recognize 25 different types were immobilized as
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parallel lines to membrane strips (Labo Bio-medical products B.V. Rijswijk, The Netherlands). 
The HPV genotyping assay was performed as described previously.10 Each experiment was 
performed with separate positive and negative PCR controls.
The LiPA strips were manually interpreted using the provided reference guide. The 
samples that tested positive using the DNA Enzyme Immuno Assay but showed no results on the 
LiPA strip were considered to be HPV X-type (i.e., genotypes not available on the LiPA strip).
Quantitative H P V  16 viral load determination
The amount of HPV 16 DNA in cervical samples was determined by real-time PCR 
using the LightCycler System (Roche). The amplification was performed in a 20 xL volume 
containing 1x Hybridization Probe mix (Roche); 3.5 mM MgCl2 20 xM concentration of each 
probe (HPV16-Fl: 5'-ACA AAA GGT TAC AAT ATT GTA ATG GGC TCT labelled with 
fluorescein and HPV16: 5'-CCG GTT CTG CTT GTC CAG CTG G -PH labelled with LC Red 
640), 50 |xM concentration of each primer (HPV16-1: 5'-GAG GAG GAG GAT GAAATA GAT 
GGT-3' and HPV16-2: 5'-GCC CAT TAA CAG GTC TTC CAA-3') and 5 xL of DNA. The 
amplification ramp included an initial hold step of 10 min followed by a denaturation cycle of 3 
sec at 95°C, an annealing cycle of 15 sec at 56°C and an elongation cycle of 9 sec at 72°C for 45 
cycles.11
For quantification of HPV 16, standard curves were generated using 10-fold dilutions of 
HPV 16 plasmid (ranging from 100 to 10,000,000 fg per reaction). The P-globin gene was 
quantified with the LightCycler Control Kit DNA, using a standard curve of 10-fold dilutions of 
human genomic DNA ranging from 3 pg to 3 ng per reaction.
Data Analysis
Normalized viral load was calculated dividing the HPV copy number by the P-globin 
copy number (based on 2 P-globin copies per cell) and was expressed as copies of virus per cell 
equivalent according the formula described by Carcopino and others (2006).12 
Viral load (HPV copies/ cell) =Number of HPV copies / Number of Pglobin copies/2
Calculations and statistical analysis were done using Epi Info 2000 v 3.3.2 (CDC, 
Atlanta, USA), Excel X® (Microsoft®, USA) and MATLAB® Statistics Toolbox 6 (The 
Mathworks, USA) programs. Statistical significance was determined by Kruskal Wallis test. Any 
P  value = 0.05 was considered significant. Lilliefors and Jarque-Bera tests were used as evidence 
for normality of the log-transformed data.
Results
We investigated whether the amount of HPV 16 DNA correlates with cervical disease 
severity by applying a real-time PCR-based assay to HPV 16 positive samples. The results were 
stratified by clinical group and the underlying distribution was examined. Figure 1 shows log­
normal cumulative distribution for HPV 16 viral load populations obtained for the 3 clinical 
groups studied. Analytical cumulative log-normal distributions determined using observed mean 
and standard deviation are also plotted for clarity. The hypothesis for log-normality in the 
observed cumulative distributions was not rejected with alpha 0.05 using Lillifors and Jarque- 
Bera tests for normality (P= 0.46/0.5 Normal, P  =0.44/0.13 LSIL and P=0.43/0.49 HSIL). Log 
normal distributions were assumed in all populations analysis for determination of confidence 
intervals shown in Table 1; however, for determination of significance of mean changes among 
groups, the non-parametric Kruskal-Wallis was used.
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The overall results are shown in Table 1 and have been stratified by condition and 
subsequently by age group and infection type within the corresponding clinical group. The main 
stratification by clinical type exhibited statistically significant differences in the populations. In 
this stratification, the highest average viral loads of HPV 16 were detected in women with HSIL 
(75 HPV DNA copies/cell). In LSIL samples an average viral load of 9 HPV DNA copies/cell was 
found, whereas an average HPV 16 viral load of 0.7 was found in women with a normal Pap 
smear result.
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Figure 1. Cumulative frequency of the viral loads of the clinical groups evaluated. The lines 
were obtained from the log-normal curves using the observed mean and standard deviations.
The amount of HPV DNA/ specimen varied significantly within a single group and 
between the different groups. The stratification by age within the clinical groups showed that the 
viral load increased with the progression of the lesion for all the groups analyzed. The highest 
mean HPV 16 viral load was found in women older than 45 years with HSIL, whereas the largest 
difference was observed between the age group less than 35 years and the rest of the groups. 
However, age differentiation was not statistically significant within the clinical groups. From the 
HPV 16 positive women with a normal Pap smear result, 61% had a single HPV 16 infection with 
an average HPV 16 viral load of 0.8 HPV DNA copies/cell and 39% had multiple HPV infections 
with an average HPV 16 viral load of 0.6 HPV DNA copies/cell.
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Table 1. Mean HPV viral load in cytoiogical normal women and in women with 
cervical lesions stratified by clinical group, age, and infection type
Overall stratification N Mean
95% CI
Kruskal W allis 
significancemin max
Clinical Norm al 23 0 .72 0 .20 2 .6 5 .E -08
group LSIL 25 8.8 2.9 27
HSIL 62 75 37 150
Subgroup stratification by age
Norm al < 35 10 0.48 0 .13 1.7 9.E-01
3 5 -4 5 6 1.1 0 .0 1 3 95
> 45 7 0 .92 0 .0 4 4 19
LSIL < 35 9 4 .6 0 .34 64 8.E-01
3 5 -4 5 11 13.7 2.8 67
> 45 5 10.3 0 .68 160
HSIL < 35 18 51.2 13 21 0 8.E-01
3 5 -4 5 22 71.4 22 23 0
> 45 22 107.0 30 380
Subgroup stratification by infection type
Normal S ing le-H P V 16 14 0 .83 0 .16 4 .3 5 8.E-01
Multiple 9 0 .58 0 .05 6 .6 0
LSIL S ing le-H P V 16 18 10.0 3.3 31 8.E-01
Multiple 7 6.1 0 .19 20 3
HSIL Sing le-H P V 16 41 79 36 176 8.E-01
Multiple 21 67 16 2 8 6
CI< confidence, interval; LSIL<low squamous intraepithelial lesions; HSIL< high 
squamous intraepithelial lesions
Among the 25 women with LSIL, 72% were found positive for single HPV infection 
with a mean HPV 16 viral load of 10.0 HPV DNA copies/cell, whereas 28% were found positive 
for multiple HPV infections with a mean HPV 16 viral load of 6.1 HPV DNA copies/cell. Women 
with HSIL had a 66% single HPV type infectivity with a mean HPV 16 viral load of 79 HPV DNA 
copies/cell and 34% multiple HPV type infectivity with a mean HPV 16 viral load of 67 HPV 
DNA copies/cell. Despite the consistent decrease in HPV 16 viral load from single to multiple 
HPV infections in all clinical groups, the differentiation within the clinical groups was not 
statistically significant.
In coinfections with HPV16, the 3 most common types found were: HPV 6 in 27% 
(10/37), HPV 18 in 19% (7/37) and HPV 74 in 16% (6/37).
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Discussion
In this study, the highest viral loads of HPV 16 were detected in women with HSIL, 
whereas lower viral loads were detected in women with negative Pap smears. These differences 
were statistically significant and suggest that the increasing amount of HPV in higher CIN stages 
indicates a dose-response association between virus viral load and lesion grade.
The analysis of the results revealed that there was a broad distribution among the HPV 
16 viral loads and no clusters were observed in any of the groups analyzed and the presence of 
dispersed values was more evident with the progression of cervical lesions. Previous studies have 
also shown that average HPV DNA copy numbers increases significantly with the grade of CIN 
mainly for HPV 16, but not for other high-risk types.4,13,14
Real-time PCR techniques have been developed to quantify HPV in clinical samples. 
Moreover, the Hybrid Capture II provides a semi-quantitative measurement of HPV-DNA and 
some studies have demonstrated that the estimated hc2 load correlates well with the precise load 
generated by real-time PCR.15-19 However, real-time PCR assays more accurately measure HPV 
16 viral load by adjusting the signal obtained for HPV-16 DNA with the amount of cellular DNA 
calculated for amplification of a human gene, therefore providing a more accurate HPV viral 
load.3,4,6,20-23 Such correction is essential if bias in viral load measurements is to be avoided because 
more cellular material can be obtained from sampling high-grade cervical lesions, thus 
potentially generating artificially higher HPV viral loads.4 However, due to low multiplicity for 
different hr-HPV types, real-time PCR methods are not (yet) suitable as a high-throughput 
“screening tool.”
In the present study, the method used allowed for normalizing the numbers of copies of 
viral DNA against the quantity of host DNA, permitting calculation of true viral load in terms of 
the number of DNA copies/cell, thus eliminating the fluctuation due to variation in cell content 
among specimens from different subjects.
Although in general the amount of HPV 16 found in patients with normal cervix was 
low, two patients had a high HPV 16 viral load (more than 100 HPV copies/cell), close to viral 
load levels observed in patients with HSIL. It would be helpful to follow-up these patients to 
differentiate transient infection from possible progression to HSIL. However, financial and 
logistic restraints partially impaired follow-up. Considering that Honduras does not have a well 
organized National Cervical Cancer Program, it was difficult for the women positive for HPV 16 
to comply with the follow-up visits and was the main limitation of this study.
In our survey, age strata analysis revealed a correlation between high viral load and 
severity of cervical lesion in all the age groups studied; even though results of this study were 
obtained with a single measurement of exposure, it was not possible to know whether an ordinal 
measurement of HPV DNA could be a predictor of progression. However, results were consistent 
with some findings observed in follow-up study designs that studied viral load of HPV and 
development of cervical cancer that indicated that measurement of viral load, as a surrogate for 
HPV persistence, may identify those women at increased risk of developing cervical lesions.3-6
Our results also showed higher HPV 16 viral loads in single infections as compared to 
multiple infections. Some studies have shown, besides viral load, an association between 
persistent HPV infection and the presence of multiple types.24 On the contrary, other studies have 
shown that clearance of a type-specific HPV infection seem to be independent of the presence of a 
coinfection with other types.25
82
The study findings have emphasized the significance of HPV 16 viral load in the risk 
determinant of cervical SIL and invasive cancer using a method that allows adjusting for 
differences in the number of cells collected for viral quantitation.
In the context of this study and given the need for additional biomarkers that could 
distinguish transient infections from those that impose a risk of progressing into cervical cancer, 
it appears appropriate to evaluate quantitative PCR assays in larger prospective studies of 
cytological normal women, which will help to determine the natural history and biology of latent 
infection.
Taken together, the data presented here could advance our understanding of the 
relationship of HPV 16 viral loads with respect to the grade of cervical disease in Honduran 
women.
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Objective. In this study, we investigated the prevalence of HPV 16 variants in Honduran women 
with normal cytology and with dysplasia and cervical cancer.
Methods. Samples identified as positive for HPV16 by SPF10-LiPA were tested for intratypic 
variants by analysis of the E6/E7 region using a novel reverse hybridization assay (line probe 
assay).
Results. We found that most HPV 16 infections in all clinical groups belong to E6 European 
variants, suggesting that HPV 16 non-European variants do not represent an additional factor 
associated with increased occurrence of high grade cervical lesions in the studied population. 
Among the 106 HPV 16 positive women analyzed, E-350G was the most prevalent variant in all 
different disease stages being present in 18% of cervical cancer, 13% of cervical intraepithelial 
neoplasia III (CIN III), 5% of CIN II, 5% of CIN I, and 20% of control samples. Mixed variants of 
HPV 16 infections were detected in 7.7% of the samples, mostly in women with normal cytology.
Conclusion. This study shows for the first time the diversity of HPV 16 variants in cervical 
samples of Honduran women.
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Introduction
In Honduras, cancer of the cervix is a major public health problem. Among women, 
cervical cancer has the highest mortality rate with a hospital cervical cancer registry of 
30.6/100,000 inhabitants.1 The role of human papillomavirus (HPV) in the etiology of cervical 
cancer has been elucidated by many epidemiological and laboratory studies.2 Most of these 
studies have found that HPV 16 is not only the most frequent viral type associated with cervical 
carcinoma and high grade squamous intraepithelial lesions (HSIL), but also the most frequent 
HPV type associated with low grade squamous intraepithelial lesions (LSIL). In addition, HPV 
16 is also prevalent in women without morphologic evidence of HPV infection but with 
detectable HPV DNA (latent infection).3 Indeed, HPV 16 produces more persistent infections 
than any other HPV type with a greater risk of progression to squamous intraepithelial lesions 
(SIL) and carcinoma.4 The phylogeny-based taxonomy of papillomaviruses (PVs) places them 
into a separate family that is further divided into genera and species. On lower taxonomic levels, 
PVs are classified as types, subtypes, and variants. Several dozen PV types have been formally 
described for non-human mammals and birds. Interestingly, more than 100 different PV types 
have been described for humans.
Eighteen HPV types are of particular interest because they are frequently associated 
with anogenital cancer and are therefore classified as high-risk HPV types.5,6 An HPV type is 
defined as a separate taxon when the nucleotide sequence of its L1 gene differs from that of any 
other HPV type by at least 10%. The additional term “subtype” defines a HPV genome whose L1 
nucleotide sequence is greater than 2%, but less than 10% different from that of the closest type. 
Although subtypes of HPV types are rare, each HPV type comprises numerous genomic variants 
that differ from one another by about 1% or a few percent within genes or hypervariable regions, 
respectively.
An important viral risk factor is the naturally occurring intratypic sequence variation 
found in PVs; although these variants differ in prevalence, biological and biochemical properties, 
their implication in the etiology of cervical cancer is still uncertain. The contribution of this 
sequence variation to variable pathogenicity is currently being investigated.7 Research on 
different populations indicates that the most studied HPV 16 variants, classified as European and 
non-European (Asian, Asian American, African-1 and African-2) have a different geographic 
distribution. Because related variants of any HPV type often cluster in specific parts of the world, 
such as Africa or East Asia, and often correlate with the distribution of major human ethnic 
groups,8-11 these genomic variants can be used in epidemiological and etiological studies to 
investigate transmission of HPV within and among populations.
Honduras's population is unique because European immigrants mixed with Native 
American Indians and Africans descendants of indentured labores brought mostly from Jamaica 
and Haiti. Consequently, its population carries the HPV variants that were originally specific to 
each ethnic group.12 Because many of these multiethnic societies originated 1 to 5 centuries ago, 
interethnic sexual contacts and racial mixing should have led to a homogenous distribution of
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different variants between different ethnic segments of each society. Still, there is some 
preferential association between specific HPV 16 and 18 variants and some ethnic groups.10,11
In this study, we investigated for the first time the prevalence of HPV 16 variants in 
Honduran women with normal cytology, dysplasia and cervical cancer using a novel reverse 
hybridization assay (line probe assay).
M aterials and methods
Study population and collection o f  specimens
The samples analyzed are part of a study that was conducted in Tegucigalpa, Honduras 
in which 760 women were enrolled to investigate HPV prevalence. Cervical samples were 
obtained from 281 female patients at San Felipe General Hospital, a referral center for cancer 
patients; patients were aged 18 to 65 years with cervical dysplasia or cervical cancer. The 
histological diagnosis based on biopsy results determined the classification of each case in the 
study. At the same time, cervical samples were also taken from 479 women with normal cervix 
and a negative Pap test, two samples per woman with cervical dysplasia or cervical cancer 
whenever possible, matched by age to a ± 5 year interval and randomly selected from cervical 
cancer screening centers and family planning clinics in low-medium socioeconomic settings in 
Tegucigalpa, Honduras.
Eligible women were those who were not currently pregnant, were willing to 
participate, had signed an informed consent form, and had no history of preneoplastic or 
neoplastic lesions of the cervix, conization or hysterectomy. A thorough physical examination 
was performed and a structured epidemiological questionnaire was administered to each woman. 
Questions pertaining to the age, occupation, lifestyles, sexual practice, and health status of the 
patients were asked. One percent of the women who were invited to participate in the study did 
not agree to be enrolled. The study was reviewed and approved by the correspondent Ethical 
Committee.
An Ayre spatula was used to obtain a cervical smear, which was immediately fixed for 
cytological examination. After the Pap test collection, additional material was obtained from the 
cervix for HPV analysis and placed in 5 mL of sterile phosphate-buffered saline (PBS, 0.82% 
(w/v); NaCl, 0.19% (w/v); Na,HPO42H2O, 0.03% (w/v); NaH2PO42H2O, adjusted to pH 7.4 with 
HCl 1 M) and 0.005% thimerosal. Upon arrival in the laboratory, cells were vortexed, centrifuged 
for 10 min at 4500 rpm, resuspended in 1 mL of PBS, centrifuged again for 10 min at 4500 rpm, 
resuspended in 0.5 mL of PBS and stored at -20 °C for further analysis. A single pathologist 
reviewed all Pap tests and biopsies.
A total of 162 samples were positive for HPV 16. Specifically, 118 (42%) samples from 
281 women with cervical dysplasia and cancer, and 44 (9%) from 479 women with normal 
cytology were HPV 16 positive.
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Among these, 110 frozen cervical DNA specimens were available for further study. 
These included 29 specimens from women with normal cytology, 8 specimens from women with 
cervical intraepithelial neoplasias (CIN) I, 16 specimens from women with CIN II, 20 specimens 
from women with CIN III and 37 specimens from women with cervical cancer. The final analysis 
was performed in 106 samples, because 4 samples did not amplify for the E6 gene.
Genital broad spectrum H PV DNA Detection
DNA extraction from the cervical smears was performed according to the Boom 
method.13 All samples were prescreened to assess DNA integrity with P-globin primers as 
previously described.14 Broad-spectrum HPV DNA amplification was performed using a short 
PCR fragment assay as previously described.14,15,16
Variant analysis o f  H PV 16positive samples
Cases identified as positive for HPV 16 were further tested for intratypic variants by 
PCR and subsequent analysis of the E6/E7 region sequences by reverse hybridization. The 
following nucleotide positions were assessed according to the HPV 16 reference sequence 
(accession number K02718): 131, 132, 143, 145, 178, 286, 289, 335, 350, 403 and 532. This 
method allowed the identification of European, Asian, Asian American, North American and 
African variants. The nomenclature was based on Yamada et al.17 The first letters and numbers 
assigned correspond to major branches (European prototype, E-P; other European variants, E; 
Asian As; African-1 and -2, Af-1 and Af-2; North American-1, NA-1; and Asian American, AA); 
a letter immediately following a dash and preceding a nucleotide position number represents the 
variation at the designated E6 nucleotide position compared to the reference sequence and the 
final letters represents E6 variations in the nucleotide 350.
Reverse Hybridization Assay (RHA)
In the RHA, biotinylated amplimers were analyzed by hybridization to DNA probes that 
are attached to nitrocellulose strips in parallel lines. Briefly, 10 ^L of the biotinylated amplimer 
was mixed with 10 ^L of denaturation solution in a plastic trough containing the genotyping 
strips. The mix was incubated for 5 min at room temperature. Two milliliters of pre-warmed (37 
°C) hybridization buffer (3 x SSC, 0.1% sodium dodecyl sulfate) was added and incubated at 
50°C±0.5°C for 1 hour. All incubations and washing steps were performed automatically in a 
ProfiBlot™ 48 T (Tecan Austria GmbH, Salzburg, Austria). The strips were washed twice for 30 
seconds and once for 30 minutes at 50±0.5°C with 2 mL of hybridization solution. After this 
stringent wash, the strips were incubated with 2 mL of alkaline phosphatase-streptavidin 
conjugate for 30 minutes at room temperature. Strips were washed twice with 2 mL of rinse 
solution and once with 2 mL of substrate buffer. Two milliliters of substrate (5-bromo-4-chloro- 
3-indolylphosphate and nitro-blue tetrazolium) was added and incubated for 30 minutes at room 
temperature. The color reaction was stopped by aspiration of the substrate buffer and addition of 2 
mL of distilled water. The strips were dried and the purple colored bands were visually scored and 
interpreted by aligning with the standard grid.
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Data analysis
To evaluate the differences between age group, clinical group, and HPV DNA type, data 
were arranged in contingency tables and analyzed by the likelihood X2 test of independence. 
When the expected values in any cell were less than five, 2x2 ways two-tailed Fisher exact test 
was used. All analysis was performed with JMP 7© (SAS Institute Inc.).
Results
A total of 106 HPV 16 positive cervical samples from Honduran women were analyzed 
for E6/E7 genetic variability by reverse hybridization to establish HPV 16 variants.
In total, seven variants of HPV 16 E6 were found: E-350G, E-350T, AA, Af, As1, 
E-and NAs being variants from the European branch the most commonly detected.
FIGURE 1. HPV-16 variants in cytologically normal women and in women with cervical lesions.
Among the 106 women analyzed, the E-350G variant was the most prevalent in all 
disease stages, being present in 18% of cervical cancer, 13% of CIN III, 5% of CIN II, 5% of 
CIN I and 20% of control samples.
92
The prevalence of the HPV 16 prototype sequence (E-350T) was 1% in CIN II and 
cervical cancer, 2% in women with normal cytology and 3% in CIN III. The non-European 
variants AA, AF1 and NA had a prevalence of 25% of all HPV 16 infections, as shown in 
Figure 1. When stratifying by European and non-European variants, the European variant is 
the most prevalent in all clinical groups, especially in women with normal cytology (23%) 
(Figure 2).
FIGURE 2. Prevalence of European and Non-European variants in different infection stages.
The proportion of subjects with advanced clinical stages (CIN III, CC) was significantly 
greater in older populations (P<0.001) (data not shown). There was however, no correlation 
between age group and variant infection (P=0.43) as shown in Table 1; only samples for which 
the number ofvalues was sufficiently large (AA and E-350G) were used in the analysis.
TABLE 1. Contingency table for age group and HPV 16 variants
Age Group AA
Count Total (%)
E350G 
Count Total (%)
>30 yr 8 (9.76) 32 (39.02)
30-50 yr 8 (9.76) 19 (23.17)
>50 yr 2 (2.44) 13 (15.85)
For each age group, the first number corresponds to the number o f cases 
represents the percentage of each variant for the total number o f cases.
for each variant; the number in parentheses
7
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The highest number of cases was observed in women younger than 30 years with 32 
cases of the E-350G variant. There was no significant relationship between the variants observed 
and the clinical stage ofthe infection (Table 2).
TABLE 2. Distributions of HPV 16 variants by clinical group.
Type n Normal/CIN 
I/CIN II
CIN -III/CC P
E-350G 64 33 31 0.66
AA 18 6 12 1
NA 3 0 3 0.54
E-350T 7 2 5 1
E-As 2 1 1 0.55
Two-tailed Fisher exact test.
Mixed variants of HPV 16 infections were detected in 7.7% of the samples, mostly in 
control samples. The AA variant prevailed (Table 3).
TABLE 3. Distribution of mixed variants infection
Condition Age, yr V arian t
Normal 35 E-350G + E-350T
Normal 30 E-350G + AA
Cervical cancer 35 E-350G + AA
Normal 34 E-As + AA
Normal 31 E-As + AA
Normal 45 E-As + AA
Normal 45 E-350G+E131G+ NA
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Discussion
In the present study, we characterized HPV 16 variants in cervical samples of Honduran 
women to evaluate intratypic variants circulating in Honduran population.
We found that most infections in all clinical groups belong to the E6 European variants, 
suggesting that non-European variants of HPV 16 do not represent an additional risk factor 
associated with increased risk of persistent infection with HPV 16 in Honduran women, because 
European and non-European variants appeared in equal frequencies among the histological types 
of lesions. Similarly, Nindl et al18 and Cruz et al19 did not find any correlation between variants 
and the severity ofthe lesion.
On the other hand, some case-control studies from Costa Rica,20 Mexico,21 Brazil,22 and 
the United States23 have found a higher risk for persistence and progression of cervical infection 
for non-European, as compared to European, HPV 16 variants.
Among the infections with European types, the apparently more aggressive variant E- 
350G predominated among the different dysplasias, cervical cancers and normal samples. This 
variant has been associated by some authors with an increased risk of persistence in infections 
produced by HPV 16 and may represent an additional factor contributing to the 
disproportionately high burden of cervical cancer in Honduran women.
On the contrary, Xi et al found that women in the ALTS trial had an increased risk of 
high-grade CIN. This increased risk was associated with HPV 16 African-2 and Asian American 
variants compared with the European variants, specifically demonstrating that the African-2 and 
Asian American variants contributed to the increased risk of CIN III.24
In our study, among the non-European variants, the Asian American variant showed 
increased prevalence in more advanced lesions. Comparison of E and As HPV 16 variants in 
Asians suggests that infection with the As variants does not carry any additional risk for cervical 
cancer.25 Variants for a given HPV type seem to segregate geographically .5,10,11
Although the reasons for geographic segregation are not clear, differences in adaptation 
of the virus to the host after many generations of exposure may be one of the factors that 
contribute to the endemic nature of HPV variants. As a consequence, certain variants of HPV 
types predominated in defined and isolated ethnic groups, such as in the people who first 
colonized the American continent 12,000 years ago.
Although it is generally recognized that multiple genital HPV types can infect patients, it 
is sometimes not appreciated that they can also carry multiple concomitant variants of the same 
HPV type. Although the prevalence of some multiple-variant infection is considered uncommon 
in North, Central and South America, some authors have observed a mixture of HPV 16 and 18
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variants reflecting the patterns of immigration into these countries.10, 11,22,26 In this study, we mainly 
found infections with two or three types in women with normal cytology.
Interestingly, Xi et al27 noticed that one variant prevails over the other variants in women 
with multiple infections of HPV 16 variants. Polyclonal HPV 16 variants have been more 
frequently found in cancers.11,18 We did not find significant differences in HPV 16 intratype variant 
distribution by age or clinical condition probably because of the limited number of samples 
analyzed.
The use of simpler and quicker methods to detect the most prevalent variants would be 
helpful for epidemiological studies looking for association. In this context, the method used in 
this study also has the advantage of detecting multiple infections in a single reaction, as detected 
in six women with normal cytology and one with cervical cancer.
One limitation of the present study is that we could not evaluate for ethnicity because all 
the samples were from mestizo (mixed European and Amerindian ancestry in Latin America) 
women. The distribution of HPV variants defined on the basis of geographical relatedness may be 
expected to be associated with ethnicity, with European variants more likely to persist in white 
women and African variants more likely to persist in African American women.8,24 In this study, 
coinfections with more than one variant of HPV 16 are likely caused by the high levels of racial 
mixing in this population because we also detected variants from all branches of geographic and 
phylogenetic relatedness.
The underlying mechanism for the race associated risk difference is presently unclear 
but it may be related to the effectiveness of the host's immune response.
Because no conclusive data have been obtained so far about the relationship of HPV 16 
molecular variants and the development of cervical cancer, it is of major importance to perform 
these types of studies to increase the knowledge of the geographic distribution and the range of 
sequence variation of these viruses that could be important in developing HPV diagnostics, the 
planning of effective vaccination programs and other therapeutic approaches to control virus- 
induced diseases. In addition, a specific intratypic polymorphism within a specific HPV 16 
lineage could be a better marker for progression than HPV 16 positivity alone.
Another limitation of the study was the small number of samples analyzed and the 
impossibility to do follow up, due to the lack of a well organized screening program and the 
inaccessibility of the women involved in the project, which reduced the statistical power of the 
analysis.
This study constitutes the first data on the diversity of HPV 16 variants in cervical 
samples from a group of Honduran women. Future studies analyzing the prevalence of HPV 16 
variants in latent infection and in the full spectrum of cervical HPV lesions in larger groups of 
patients are warranted, especially in a country with a high incidence of cervical cancer such as 
Honduras.
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Summary and General Discussion
Cervical cancer represents an important global public health problem, as it is a common 
cause of death in women all over the world.1 In close to 60% of the countries, mainly in less 
developed regions as Honduras, cervical cancer dominates as the first or second cancer site. 
Persistent infections with certain high-risk human papillomavirus (hr-HPV) genotypes play an 
essential role in cervical cancer carcinogenesis.2 Hr-HPV assessment, either by DNA detection 
and/or HPV genotyping could enhance the cervical cancer detection and prevention. 
Furthermore, primary prevention of cervical cancer through the introduction of HPV vaccines 
looks very promising although the current vaccines merely protect against two hr-HPV 
genotypes, leaving a niche for at least 11 other hr-HPV's.3 Honduras is a country with a high 
incidence of cervical cancer, where HPV vaccination campaigns could benefit a large proportion 
of Honduran women in risk for this disease and where a comprehensive program to transform a 
prevention strategy into appropriate, accessible and applied practices is warranted. We engaged 
with this thesis, in order to create a baseline for these purposes to investigate the prevalence, type 
distribution of HPV, molecular variants of HPV 16 and co-factors involved in the process of 
carcinogenesis of HPV infections in Honduran women.
In chapter 1 the current knowledge on cervical cancer, HPV and virus immunology is 
described. It is estimated that over 1 million women worldwide currently have cervical cancer, 
most of who have not been diagnosed, or have no access to treatment that could cure them or 
prolong their life.4
In many developing countries, access to health services is limited and screening for 
cervical cancer either is non-existent or reaches only few of the women who need it. In these 
areas, cervical cancer is the most common cancer in women and the leading cause of cancer 
death. Left untreated, invasive cervical cancer is almost always fatal, causing enormous pain and 
suffering for the individual and having significant adverse effects in the welfare of their families 
and communities. Cervical cancer occurs worldwide, but the highest incidence rates are found in 
Central and South America, The Caribbean, Eastern Africa, South and South-East Asia, and 
Melanesia.5
There are an estimated 27,500 deaths each year in the Americas from cervical cancer.6 
Globally cervical cancer has been estimated to account for 2.1% of deaths among women aged 
25-64 but in Latin America it accounts for 3.8% ofthese deaths. In the year 2000, estimates ofthe 
age standardized incidence and mortality rate of cervical cancer in Honduras were 30.6 cases per 
100,000 inhabitants and 15 per 100,000 inhabitants respectively.7 Universally agreed upon risk 
factors for cervical cancer include HPV, having multiple sexual partners (or a partner who has 
multiple partners), early age at first intercourse, a history of sexually transmitted diseases, low 
socioeconomic or educational status and smoking.8 Due to the widespread nature of infection, 
HPV-induced malignancies remain a major public health issue throughout the world, mainly in 
Developing countries.
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To estimate type-specific HPV prevalence and its cofactors among Honduran women 
with normal cytology in order to provide valuable information to health policymakers about the 
epidemiology of this important sexually transmitted infection, a study was conducted in 591 
women with normal cytology from Tegucigalpa, Honduras who were interviewed and tested for 
HPV using the SPF10 LiPA25 (chapter 2). A structured epidemiological questionnaire was 
administered to each woman. The overall HPV prevalence was 51%. Twenty-three types of HPV 
were detected; HPV 16, 51, 31, 18, and 11 were the most common, which confirmed that there is 
great variability in the range of HPV types detected in exfoliated cervical cells at a population 
level in Latin America.
The highest prevalence of cancer associated HPV types (15.0%) was found in the 
women less than 35 years. Besides the association with age, the main independent predictors of 
HPV infection were the lifetime number of sexual partners and having a low socioeconomic 
status and less than 5 previous Pap smears, supporting the preponderant role of cervical screening 
in the effective control of cervical cancer. The establishment of a well-characterized population 
with regard to the community prevalence of type-specific HPV infection will provide a valuable 
baseline for monitoring population effectiveness of an HPV vaccine.
Since information on hr-HPV prevalence is limited, more studies on the prevalence of 
HPV infection in Honduras are needed. In Chapter 3, we studied HPV genotypes in women with 
cervical intraepithelial lesions and cervical cancer in Honduras, and identified epidemiological 
co-factors which contribute, besides HPV, to the development of cervical cancer is described, in 
order to have a baseline for Public Health authorities for the implementation of HPV vaccine 
campaigns.
Among the 289 cases analyzed for HPV using the SPF10LiPA25 system, 139 had LSIL, 60 
had HSIL, and 90 had CC. HPV DNA was detected in 113 (81%) LSIL, 58 (97%) and 84 (93%) 
women with CC. Twenty-five different HPV genotypes were found. HPV 16 was detected in 
41% of CC, 35% of HSIL and 24% of LSIL. HPV 18 was found in 9% of CC, in 4% of HSIL, and 
5% of the women with LSIL. A direct positive association between lifetime sexual partners and 
HPV infection was found. An association with age and a linear dose-response for HPV infection 
with the number of pregnancies was found, when considering all HPV types and all age groups 
combined.
In the initial phase of the project, a study was initiated to determine the prevalence of 
HPV and C. trachomatis in female university students in Honduras. The latter pathogen being the 
most common sexually transmitted bacterial infection in the world and sexually active young 
persons are at the highest risk, (Chapter 4). For this purpose, 100 female university students in 
Honduras were tested for the presence of these pathogens. Twenty-eight percent were positive for 
HPV and 6% were positive for C. trachomatis. These results show that genital HPV and C. 
trachomatis infections are very common among sexually active young women in Honduras. Of 
the 28 women positive for HPV, 22 contained more than one HPV type.
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In agreement with the results of previous studies, we found that the prevalence of HPV in 
women less than 25 years of age was significantly higher than in older women. Positivity for C. 
trachomatis was also higher in students less than 25 years than in older women. It is vital to 
promote extensive public awareness campaigns among sexually active women. This will also 
help in determining the prevalence of sexually transmitted infections and improving prevention 
strategies.
To evaluate ROCHE HPV Linear Array assay performance for detection of HPV type 
specific prevalence among young women and their association with possible risk factors, we 
performed a study described in chapter 5. Four hundred university students from the 
Universidad Nacional Autonoma de Honduras (UNAH) aged 18 to 35 years were HPV typed 
using the Roche LINEAR ARRAY HPV Genotyping Test, to differentiate 37 HPV genotypes. 
HPV DNA was detected in 45% of students with normal cytology, from which 73% were infected 
with high risk types and 46% presented multiple infections. Overall, 36 genotypes were 
encountered of which HPV type 16, HPV type 51, HPV type 84, HPV type 66 and HPV type 39 
being the most common. There was a marked decline in the prevalence of both multiple and high 
risk HPV infection with age. The factors independently associated with a risk of being HPV 
positive, excluding age and Pap smear result, were related to sexual behavior and smoking habits. 
We concluded that the Roche HPV Line Linear Array has proven to be a valuable tool for HPV 
genotyping. Our results demonstrated that genital HPV infection is common among sexually 
active young university women. HPV genotyping is important for epidemiological studies and to 
determine the efficacy of the HPV vaccine in the population.
Besides the importance of specific HPV genotypes, other viral cofactors as viral load 
may influence the progression likelihood of an HPV infection to cervical cancer. In chapter 6, the 
relationship between HPV 16 viral loads with respect to the grade of cervical disease in Honduran 
women was investigated. A real-time PCR allowing quantification of both HPV 16 genome and 
P-globin gene was used. The data in 87 women with cervical dysplasia or cervical cancer and in
23 women with a normal Pap smear were evaluated. The highest average of HPV 16 viral load was 
detected in women with high grade squamous intraepithelial lesions (HSIL), whereas lower viral 
loads were detected in women with normal Pap smears. These differences were statistically 
significant and suggest that the increasing amount of HPV in higher CIN stages indicates a dose- 
response association between viral load and lesion grade. The analysis of the results revealed that 
there was a broad distribution among the HPV 16 viral load and no clusters were observed in any 
of the groups analyzed. The presence of dispersed values was more evident with the progression 
of cervical lesions, which could indicate a dose-response association between viral load and 
precancerous lesion grade.
In our survey, age strata analysis revealed a correlation between high viral load and 
severity of cervical lesion in all the age groups studied; even though results of this study were 
obtained with a single measurement of exposure, it was not possible to know whether an ordinal 
measurement of HPV DNA could be a predictor of progression. The study findings have
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emphasized the significance of HPV 16 viral load in the risk determinant of cervical SIL and 
invasive cancer using a method that allows adjusting for differences in the number of cells 
collected for viral quantification.
In the context of this study and given the need for additional biomarkers that could 
distinguish transient infections from those that impose a risk of progressing into cervical cancer, it 
appears appropriate to evaluate quantitative PCR assays in larger prospective studies of 
cytological normal women, which will help to determine the natural history and biology of latent 
infection.
Taken together, the data presented here could advance our understanding of the 
relationship of HPV 16 viral load with respect to the grade of cervical disease in Honduran 
women. Besides viral load, an important viral risk factor is the naturally occurring intratypic 
sequence variation found in HPV; although these variants differ in prevalence, biological and 
biochemical properties, their implication in the etiology of cervical cancer is still uncertain. The 
contribution of this sequence variation to variable pathogenicity is being investigated. In this 
context in chapter 7, we characterized HPV 16 variants in Honduran women with normal 
cytology and with dysplasia and cervical cancer in order to evaluate intratypic variants 
circulating in our population. Samples were identified as positive for HPV16 by analysis of the 
E6/E7 region using a novel reverse hybridization assay (LiPA).
We found that most HPV-16 infections in all clinical groups comprised E6 European 
variants, suggesting that HPV-16 non European variants do not represent an additional factor 
associated with increased occurrence of high grade cervical lesions in the studied population. 
Among the 106 HPV-16 positive women analyzed, the E-350G was the most prevalent variant in 
all different disease stages being present in 18% of cervical cancer, 13% of cervical intraepithelial 
neoplasia III, 5% of cervical intraepithelial neoplasias II, 5% of cervical intraepithelial neoplasia 
grade I, and 20% of control samples. This variant has been associated by some authors with an 
increased risk of persistence in infections produced by HPV-16 and may represent an additional 
factor contributing to the disproportionately high burden of cervical cancer in Honduran women. 
In our study, among the non-European variants, the Asian American showed increased 
prevalence in more advanced lesions. Mixed HPV-16 variant infections were detected in 7.7% of 
the samples, mostly in women with normal cytology. Although it is generally recognized that 
patients can be infected by multiple genital HPV types, it is sometimes not appreciated that they 
can also carry concomitant multiple variants of the same HPV genotype. Even though the 
prevalence of some multiple-variant infection is considered uncommon in North, Central and 
South America, some authors have observed mixture of HPV-16 and 18 variants reflecting the 
patterns of immigration into these countries. In this study we found infections with two or three 
types mainly in women with normal cytology.
The use of simpler and rapid methods to detect the most prevalent variants would be 
helpful for epidemiological studies looking for association. In this context, the method used in 
this study also has the advantage of detecting multiple infections in a single reaction, as detected
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in six women with normal cytology and one with cervical cancer. Also a specific intratypic 
polymorphism within a specific HPV 16 lineage could be a better marker for progression than 
HPV 16 positivity alone.
It is of major importance to perform these type of studies in order to increase the 
knowledge of the geographical distribution and the range of sequence variation of these viruses 
which could be important in developing HPV diagnostics, the planning of effective vaccination 
programs and other therapeutic approaches to control virus-induced diseases.
This study constitutes the first data on the diversity of HPV-16 variants in cervical 
samples of a group of Honduran women; future studies analyzing the prevalence of HPV-16 
variants in latent infection and in the full spectrum of cervical HPV lesions in larger groups of 
patients, are warranted, especially in a country with a high incidence of cervical cancer such as 
Honduras.
As it happens in most developing countries, in Honduras some cultural factors can be 
related to this high HPV prevalence, especially lack of education, early start of sexual activity, 
multiparity and the prevalence of attitudes, misconceptions and beliefs that constrain people 
from discussing diseases of the genital tract. In most developing countries, access to health 
services is limited and screening for cervical cancer either is nonexistent or reaches few of the 
women who need it. A well-functioning health system, with the necessary equipment and trained 
providers, is essential for prevention activities, screening and diagnosis, linkages for follow-up 
and treatment, and palliative care.
The results emanating from this thesis may assist the public health authorities in 
planning prophylactic and therapeutic strategies to prevent cervical cancer, including HPV 
diagnosis and rational vaccine strategies. The establishment of a well-characterized population 
with regard to the community prevalence of type-specific HPV infection will provide a valuable 
baseline for monitoring population effectiveness of an HPV vaccine. In order to maximize the 
cost-effectiveness of HPV vaccination programmes, it is also important to understand the 
distribution of the major HPV types in various geographic regions.
Previous studies performed in other populations have suggested that although the 
benefit of the vaccines is clearly highest when given to an HPV naive population, there is still a 
significant reduction in HPV-related precancerous lesions when given to the general population 
regardless of HPV status.9 Considering the proportion of abnormal lesions found to be associated 
with HPV 16 and/or 18 infection in this population, it could be estimated that the implementation 
of the prophylactic vaccines against the HPV strains 16 and 18 have the potential of preventing at 
least a quarter of LSIL, one third of HSIL and about half of cervical cancer cases in Honduras.
The advent of new technologies for HPV DNA testing and the introduction of the HPV 
vaccines have increased optimism about the potential for effective disease control in low- 
resource settings. In low resource countries where cervical cancer screening programmes and
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treatments are scarce or absent, HPV vaccines raise considerable expectations.3 Since HPV types 
vary between regions in the world and the strains targeted by the currently marketed vaccines 
may not prevail in low-resource countries, more extensive epidemiologic studies of HPV-typing 
are needed in order to contribute to the efficacy of the vaccines in this population.
The efficacy and efficiency of the two HPV vaccines available today have been proven 
to reach 100%, meaning that close to all cervical abnormalities and cervical cancers caused by 
either HPV 16 or 18 (and partly other HPV genotypes by cross-immunity) can be prevented.10 In a 
population as Honduras with such a high cervical cancer burden, the introduction of vaccine 
campaigns will thus lead to a significant reduction in the incidence of cervical cancer. It is 
therefore inconceivable that due to the high costs of vaccination, this vaccine will not be available 
for low-income countries despite the need for it.
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Sumario
El cáncer cervicouterino es un importante problema de salud pública, ya que es una 
causa común de muerte en mujeres en todo el mundo. En alrededor del 60% de los países, 
principalmente en las regiones menos desarrolladas como Honduras, el cáncer cervical 
representa el primero o segundo tipo de cáncer más común en mujeres. Las infecciones 
persistentes con ciertos virus del papiloma humano de alto riesgo (VPH-AR) desempeñan un 
papel esencial en la carcinogenesis del cáncer cervical.
La evaluación de VPH-AR, ya sea mediante la detección de ADN y/o genotipificación 
del VPH podría mejorar la detección del cáncer de cuello uterino y su prevención. Por otro lado, la 
prevención primaria del cáncer cervical a través de la introducción de vacunas contra el VPH es 
muy prometedora a pesar de que las vacunas actuales sólo protegen contra dos genotipos de VPH 
de alto riesgo. Al menos otros 11 VPH de alto riesgo además del tipo 16 y 18 circulan en 
Honduras, un país con una alta incidencia de cáncer cervical. La campaña de vacunación contra 
el VPH podría beneficiar a una gran proporción de mujeres hondureñas en riesgo de esta 
enfermedad y se justifica por lo tanto un programa integral de desarrollo para una estrategia de 
prevención.
El propósito de esta tesis es ampliar la base de referencia que se tenía por estudios 
previos, proporcionando datos actualizados de prevalencia, distribución de los genotipos de VPH 
y cofactores que intervienen en el proceso de la carcinogenesis de las infecciones por VPH en las 
mujeres hondureñas, así como investigar la carga viral del virus y las variantes moleculares de 
VPH 16.
En el capítulo 1, se describe el conocimiento actual sobre el cáncer cervical, el VPH y la 
inmunología relacionada con esta enfermedad. Se estima que más de 1 millón de mujeres en todo 
el mundo actualmente tienen cáncer de cuello uterino, en cuya mayoría aún no han sido 
diagnosticados, o las mujeres no tienen acceso al tratamiento que podría curar la enfermedad o 
prolongar su vida.
En muchos países en desarrollo, el acceso a los servicios de salud es limitado y la detección 
de cáncer cervical o es inexistente o llega sólo a algunas de las mujeres que lo necesitan. En estas 
áreas, el cáncer cervicouterino es el cáncer más común en las mujeres y la principal causa de 
muerte por cáncer. Si no se trata, el cáncer invasor del cuello uterino es casi siempre fatal, 
causando enorme dolor y sufrimiento para el individuo y tienen efectos adversos importantes en 
el bienestar de sus familias y en sus comunidades.
El cáncer de cuello uterino se produce en todo el mundo, pero las tasas de incidencia más 
alta se encuentran en Centro y Sudamérica, el Caribe, África oriental, Asia meridional y 
sudoriental, y Melanesia. Se estima que hay 27,500 muertes cada año en América por cáncer 
cervicouterino. A nivel mundial se han estimado en 2.1% las muertes por éste cáncer entre las
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mujeres de 25-64 años, pero en América Latina representa el 3.8% de estas muertes. En el año 
2000, las estimaciones de la incidencia ajustada por edad y tasa de mortalidad de cáncer cervical 
en Honduras fueron 30.6 casos por 100.000 habitantes y 15 por 100.000 habitantes 
respectivamente.
Universalmente se han aceptado como factores de riesgo para el cáncer cervical: el VPH, 
tener múltiples parejas sexuales (o una pareja que tiene múltiples parejas), la edad temprana en la 
primera relación sexual, antecedentes de enfermedades de transmisión sexual, el bajo nivel 
socioeconómico o educativo y fumar.
La infección por VPH sigue siendo un importante problema de salud pública en todo el mundo, 
principalmente en los países en desarrollo debido a su naturaleza generalizada por inducir 
tumores malignos.
Para estimar la prevalencia de VPH tipo-específica y sus cofactores en las mujeres con 
citología normal se realizó un estudio en 591 mujeres con citología normal de Tegucigalpa, 
Honduras, que fueron encuestadas y sus muestras analizadas por ADN de el VPH usando el 
LiPA25 SPF10 (capítulo 2).El propósito del estudio es proporcionar información valiosa para las 
políticas de salud sobre la epidemiología de esta importante infección de transmisión sexual. La 
prevalencia global de VPH fue del 51%. Veinte y tres tipos de VPH fueron detectados; los 
genotipos de VPH 16, 51, 31, 18 y 11 fueron los más comunes, lo que confirmó que existe una 
gran variabilidad de tipos de VPH detectados en las células cervicales exfoliadas de la población 
en América Latina.
La prevalencia más alta de tipos de VPH asociados a cáncer (15.0%) se encontró en las 
mujeres menores de 35 años. Además de la asociación con la edad, los principales factores 
predictivos independientes de la infección por VPH fueron el número de parejas sexuales a lo 
largo de su vida, tener un nivel socioeconómico bajo y menos de 5 pruebas de Papanicolaou 
anteriores, lo que confirma el papel preponderante del tamizaje en el control eficaz del cáncer de 
cuello uterino. El establecimiento de una población bien caracterizada en lo que respecta a la 
prevalencia de infección por VPH en la comunidad y de los tipos específicos circulantes servirán 
de base para controlar la eficacia en la población de una vacuna contra el VPH.
Dado que la información sobre la prevalencia de VPH-AR es limitada, son necesarios 
más estudios relacionados con la prevalencia de infección por VPH en Honduras. En el capítulo 
3, estudiamos los genotipos del VPH en mujeres con lesiones intraepiteliales cervicales y cáncer 
de cuello uterino en Honduras y se identificaron cofactores epidemiológicos que contribuyen, 
además del VPH, para el desarrollo del cáncer cervical a fin de tener información base que sirva a 
las autoridades de Salud Pública para la realización de campañas de vacunación contra el VPH. 
Entre los 289 casos analizados para detectar el VPH usando el sistema de SPF10 LiPA25, ADN 
de VPH fue detectado en 113 (81%) lesiones intraepiteliales de bajo grado (LIBG), 58 (97%) 
lesiones intraepiteliales de alto grado (LIAG) y 84 (93%) mujeres con cáncer cervical (CC). 
Veinte y cinco diferentes genotipos de VPH fueron encontrados. VPH 16 se detectó en el 41% de
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CC, el 35% de LIAG y 24% de LIBG. VPH 18 fue encontrado en 9% de CC, 4% de LIAG, y 5% 
de las mujeres con LIBG. Se encontró una asociación directa entre número de parejas sexuales y 
la infección con VPH. Una asociación con la edad y una dosis-respuesta lineal para la infección 
del VPH con el número de embarazos se detectó, al considerar todos los tipos de VPH y todos los 
grupos de edad combinados.
En la fase inicial del proyecto, se realizó un estudio para determinar la prevalencia de VPH 
y C. trachomatis en estudiantes universitarias de Honduras. Este último es el patógeno más 
común causante de infección bacteriana de transmisión sexual en el mundo y los jóvenes 
sexualmente activos están expuestos al mayor riesgo, (capítulo 4). En el estudio se incluyeron
100 estudiantes femeninas de la Universidad Nacional Autónoma de Honduras para determinar la 
presencia de estos patógenos. Veinte y ocho por ciento fueron positivas para VPH y 6% fueron 
positivas para C. trachomatis. Estos resultados demuestran que el VPH genital y las infecciones 
por C. trachomatis son muy comunes entre las mujeres jóvenes sexualmente activas de 
Honduras. De las 28 mujeres positivas para el VPH, 22 contenían más de un tipo de VPH.
De acuerdo con los resultados de estudios previos, se encontró que la prevalencia del VPH 
en mujeres menores de 25 años de edad fue significativamente mayor que en las mujeres 
mayores. La positividad para C. trachomatis fue también mayor en las estudiantes menores de 25 
años que en las mujeres mayores. Es de vital importancia promover campañas de información 
pública entre las mujeres sexualmente activas y mejorar las estrategias de prevención.
Para evaluar la prueba LA VPH de ROCHE para detección y genotipificación de VPH, 
realizamos un estudio para determinar la prevalencia de genotipos específicos de VPH en 
estudiantes universitarias femeninas y su asociación con posibles factores de riesgo, descrito en 
el capítulo 5. Cuatrocientas estudiantes universitarias de la Universidad Nacional Autónoma de 
Honduras (UNAH) de entre 18 y 35 años fueron analizadas con el ensayo LA VPH de Roche que 
permite diferenciar 37 genotipos de VPH. ADN de VPH se detectó en 45% de las estudiantes 
universitarias citológicamente normales, de las cuales 73% estaban infectadas con tipos de alto 
riesgo y 46% presentaron infecciones múltiples. En general, se encontraron 36 genotipos de 
VPH, de los cuales, los tipos 16, 51, 84, 66 y 39 fueron los más comúnmente detectados. Hubo un 
marcado descenso en la prevalencia de infección por VPH con la edad. Los factores 
independientemente asociados con el riesgo de positividad por VPH, exceptuando la edad y el 
resultado de Papanicolaou, se relacionaron con el comportamiento sexual y el hábito de fumar. 
Llegamos a la conclusión de que la prueba LA de ROCHE es una herramienta valiosa para 
determinar el genotipo del VPH. Nuestros resultados demuestran que la infección genital por 
VPH es muy común entre las mujeres jóvenes sexualmente activas. La genotipificación del VPH 
es importante para los estudios epidemiológicos y para determinar la eficacia de la vacuna contra 
el VPH en la población.
Además de la importancia de determinados genotipos de VPH, otros cofactores virales 
como la carga viral pueden influir en la progresión de una infección por VPH a cáncer cervical.
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En el capítulo 6, se investigó la relación entre el VPH 16 y la carga viral en relación con 
el grado de enfermedad cervical en las mujeres hondureñas. Se utilizó PCR en tiempo real para la 
cuantificación de VPH 16 y el gen de P-globina. Se evaluaron resultados de 87 mujeres con 
displasia cervical o cáncer de cuello uterino y de 23 mujeres con citología normal. El promedio 
más alto de carga viral de VPH 16 se detectó en mujeres con lesiones escamosas intraepiteliales 
de alto grado (LIAG), mientras que cargas virales más bajas se detectaron en mujeres con 
citología normal. Estas diferencias fueron estadísticamente significativas y sugieren que la 
creciente cantidad de VPH en las etapas avanzadas de NIC indica una asociación dosis-respuesta 
entre la carga viral y el grado de lesión. Los resultados del estudio ponen en relieve la importancia 
de la carga viral de VPH 16 como factor determinante de riesgo de neoplasia intraepitelial 
cervical y cáncer invasor.
En el contexto de este estudio y dada la necesidad de biomarcadores adicionales que 
permitan distinguir infecciones transitorias de aquellas que imponen un riesgo de progresión a 
cáncer de cuello uterino, se estima oportuno evaluar los ensayos de PCR cuantitativa en estudios 
prospectivos de mujeres con citología normal, lo que ayudará para determinar la historia natural 
de la enfermedad y la biología de la infección latente.
En general, los datos presentados podrían mejorar nuestra comprensión de la relación de 
la carga viral de VPH 16 con el grado de enfermedad cervical en las mujeres hondureñas. Además 
de la carga viral, un importante factor de riesgo es la variación de la secuencia intratípica natural 
de VPH, aunque estas variantes difieren en la prevalencia, biología y bioquímica, su implicación 
en la etiología del cáncer de cuello uterino sigue siendo incierto. La contribución de la variación 
de la secuencia con la patogenicidad sigue en investigación. En este contexto, en el capítulo 7, se 
caracterizaron variantes del VPH 16 de mujeres hondureñas con citología normal y con displasia 
y cáncer de cuello uterino con el fin de determinar las variantes intratípicas que circulan en 
nuestra población. Las muestras fueron identificadas como positivas para el VPH 16 mediante el 
análisis de la región E6/E7 utilizando un nuevo ensayo de hibridación reversa (LiPA).
Encontramos que la mayoría de las infecciones por VPH 16 en todos los grupos clínicos 
obtenidos pertenecían a las variantes E6 europeas, lo que sugiere que las variantes no europeas no 
representan un factor adicional asociado con mayor incidencia de lesiones cervicales de alto 
grado en la población estudiada. Entre las 106 mujeres VPH 16 positivo analizadas, la E350G fue 
la variante más frecuente en todos los estadíos de la enfermedad, está presente en 18% de los 
casos de cáncer cervical, 13% de la neoplasia cervical intraepitelial III, 5% de neoplasias 
intraepiteliales cervicales II, 5% de la neoplasia intraepitelial cervical grado I, y 20% de las 
muestras control. Esta variante ha sido asociada por algunos autores con un mayor riesgo de 
persistencia en las infecciones producidas por VPH 16 y puede representar un factor adicional 
que contribuye a la gran cantidad de cáncer de cuello uterino en las mujeres hondureñas. En 
nuestro estudio, entre las variantes no europeas, la asiático-americana mostró una mayor 
prevalencia en las lesiones más avanzadas. Infecciones por múltiples variantes de VPH 16 se 
detectaron en 7.7% de las muestras analizadas, sobre todo en mujeres con citología normal. Si
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bien la prevalencia de infecciones por múltiples variantes se considera poco común en Norte, 
Centro y Sur América, algunos autores han observado mezcla de variantes de VPH 16 y 18, que 
reflejan los patrones de inmigración en estos países. En este estudio encontramos infecciones con 
dos o tres tipos principalmente en mujeres con citología normal.
El uso de métodos sencillos y rápidos para la detección de las variantes más prevalentes 
sería de gran ayuda para los estudios epidemiológicos. En este contexto, el método utilizado en 
este estudio también tiene la ventaja de permitir la detección de infecciones múltiples en una sola 
reacción, en este estudio se detectaron múltiples infecciones en seis mujeres con citología normal 
y una con cáncer de cuello uterino.
Es de gran importancia llevar a cabo este tipo de estudios con el fin de extender el 
conocimiento de la distribución geográfica y el rango de variación de la secuencia de estos virus 
que podrían ser importantes en el desarrollo de métodos diagnósticos de VPH, la planificación de 
programas de vacunación eficaces y otros enfoques terapéuticos para control de las 
enfermedades inducidas por el virus.
Este estudio proporciona los primeros datos sobre la diversidad de las variantes del VPH
16 en muestras cervicales de un grupo de mujeres hondureñas; estudios futuros sobre la 
prevalencia de variantes del VPH 16 en la infección latente y en todo el espectro de las lesiones 
cervicales de VPH en grupos más grandes de pacientes son necesarios, especialmente en un país 
con una alta incidencia de cáncer de cuello uterino como Honduras.
Como sucede en la mayoría de los países en desarrollo, en Honduras algunos factores 
culturales pueden estar relacionados con esta alta prevalencia de VPH, sobre todo la falta de 
educación, inicio temprano de la actividad sexual, la multiparidad y la prevalencia de actitudes, 
prejuicios y creencias que limitan a la gente para hablar de las enfermedades del tracto genital. En 
la mayoría de los países en desarrollo, el acceso a los servicios de salud es limitado y la detección 
del cáncer de cuello uterino o es inexistente o no llega a todas las mujeres que lo necesitan. Un 
buen funcionamiento del sistema de salud es esencial para las actividades de prevención, 
detección y diagnóstico, el seguimiento y tratamiento y los cuidados paliativos.
Los resultados que se deriven de esta tesis pueden ayudar a las autoridades de salud pública 
en la planificación de estrategias profilácticas y terapéuticas para prevenir el cáncer cervical, 
incluyendo el diagnóstico de VPH y la implementación de la vacuna. Estudios previos realizados 
en otras poblaciones han sugerido que, si bien el beneficio de las vacunas es claramente mayor 
cuando se administra a una población que nunca ha sido expuesta al VPH, todavía hay una 
reducción significativa en las lesiones precancerosas relacionadas con el VPH cuando se 
administra a la población general, independientemente de su condición. Teniendo en cuenta la 
proporción de lesiones anormales que se encuentran asociadas con el VPH 16 y/o 18 la en esta 
población, se podría estimar que la aplicación de las vacunas profilácticas contra los genotipos de 
VPH 16 y 18, tienen el potencial de prevenir más de un cuarto de las lesiones de bajo grado, un 
tercio de las lesiones de alto grado y aproximadamente la mitad de casos de cáncer cervical en
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Honduras.
Las dos vacunas contra el VPH disponibles en la actualidad han demostrado alcanzar el 
100% de eficacia y eficiencia, lo que significa que se pueden prevenir cerca de todas las 
anomalías del cuello uterino y el cáncer cervical causado por VPH 16 o 18. En una población 
como la hondureña con una alta carga de cáncer cervical, la introducción de las campañas de 
vacunación, darían lugar a una reducción significativa en la incidencia de ésta enfermedad. Por 
tanto, es inconcebible que debido a los elevados costos de la vacunación, esta vacuna no esté 
disponible en los programas de vacunación gratuita en los países de bajos ingresos.
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